- As a generalization, any drug that can block a pathway, without producing serious side effects, may serve as a candidate treatment for all of the diseases that are driven by the pathway.
- Individuals in the early stages of common diseases, before multiple disease pathways converge to produce an intractable clinical phenotype, may be particularly amenable to treatments that interfere with the pathways that promote the ensuing steps in pathogenesis.
Devoted to the topic of data specification (including data organization, data description, data retrieval and data sharing) in the life sciences and in medicine.
Monday, February 5, 2018
Treat the Pathway, not the Gene (from Precision Medicine and the Reinvention of Human Disease)
Treat the key pathway, not the genetic mutation (from Precision Medicine and the Reinvention of Human Disease)
Some of the earliest and most successful Precision Medication drugs have targeted specific
mutations occurring in specific subsets of diseases. One such example is ivacaftor, which targets
the G551D mutation present in about 4% of individuals with cystic fibrosis [135]. It is
seldom wise to argue with success, but it must be mentioned that the cost of developing a
new drug is about $5 billion [136]. To provide some perspective, $5 billion exceeds the total
gross national product of many countries, including Sierra Leone, Swaziland, Suriname,
Guyana, Liberia, and the Central African Republic. Many factors contribute to the development
costs, but the most significant is the incredibly high failure rate of candidate drugs.
About 95% of the experimental medicines that are studied in humans fail to be both effective
and safe. The costs of drug development are reflected in the rising costs of drugs.
When a new drug is marketed to a very small population of affected individuals, the cost of
treating an individual may be astronomical. Americans should not pin their hopes on the belief
that one day, the FDA or CMS (which administrates Medicare) will step in and put a stop
to the price rises. The Food and Drug Administration can approve or reject drugs, but it does
not regulate prices. Likewise, Medicare is not permitted to consider cost when it decides
whether a treatment can be covered. Knowing this, some notable pharmaceutical
companies have raised the prices of medications far beyond their manufacturing costs
[137–139]. In effect, the cost of curing curable diseases may exceed our ability to pay for those
cures [139].
It is strongly in the interests of society to develop drugs that have the widest possible
user market [140]. Drugs that target a mutation that is specific for a few individuals with a
rare disease, or a tiny subpopulation of individuals who have a common disease, are highly
problematic.
Our experiences with disease convergence teach us that clinical phenotypes are influenced
by the activities of pathways and are seldom restricted to a specific mutation in a specific
gene. We know this because rare diseases that exhibit locus heterogeneity affect different
genes, but often target the same pathway. Likewise, acquired phenotypes of genetic diseases
often involve inhibitors of the same key pathways that drive their genetic counterparts, without
involving the protein product of the genetic form of the disease. We also know that the
acquired version of most genetic diseases account for the bulk of disease occurrences. Therefore,
if we want to develop treatments that benefit the greatest number of individuals affected
by a disease, it would be far more practical to find treatments that target the disease-driving
pathways than to design drugs that target a specific gene mutation involved in a small subset
of affected patients.
Before closing, here are a few points worth considering (to be discussed in later blogs):
Sunday, February 4, 2018
National Patient Identifiers (from Precision Medicine and the Reinvention of Human Disease)
Readers from outside the United States are probably wondering
why the United States agonizes over the problem of patient identification. In many other
countries, individuals are given a unique national identifier, and all medical data associated
with the individual is kept in a central data repository under the aegis of the government’s
health service. A single, permanent identifier is used by a patient throughout life, in every
encounter with a hospital, clinic, or private physician. As a resource for researchers, the national
patient identifier ensures the completeness of data sets and eliminates many of the
problems associated with poorly implemented local identifier systems.
In the United States, there has been fierce resistance to the idea of national patient identifiers.
The call for a national patient identification system is raised from time to time. The benefits
to patients and to society are many. Regardless, US citizens are reluctant to have an
identifying number that is associated with a federally controlled electronic record of their
private medical information. In part, this distrust results from the lack of any national insurance
system in the United States. Most health insurance in the United States is private, and
private insurers have wide discretion over the fees and services provided to enrollees. There
is a fear that if there were a national patient identifier with centralized electronic medical
records, insurers would withhold reimbursements or raise premiums or otherwise endanger
the health of patients. Because the cost of US medical care is the highest in the world, medical
bills for uninsured patients can quickly mount, impoverishing individuals and families.
Realistically, though, no data is safe. Medical records can be stolen, and governments can demand
access to medical records, when necessary [See Lewin T. Texas orders health clinics to turn over patient data. The New York Times; October 23, 2015].
Life has its compromises. Everyone wants their privacy and we all get angry when we hear
that our confidential information has been stolen. Data breaches today may involve hundreds
of millions of confidential records. The majority of Americans have had social security numbers,
credit card information, and private identifiers (e.g., birth dates, city of birth, names of
relatives) misappropriated or stolen. It’s natural to object to anything that might jeopardize
our privacy. Nonetheless, we must ask ourselves the following: “Is it rational to forfeit the very
real opportunity of developing new safe and effective treatments for serious diseases, for the
very small likelihood that someone will crack your deidentified research record and somehow
leverage this information to your disadvantage?”
Suppose everyone in the United States were given a choice: you can be included in a
national patient identifier system, or you can opt out. Most likely, there would be many millions
of citizens who would opt out of the offer, seeing no particular advantage in having a
national patient identifier, and sensing some potential harm. Now, suppose you were told
that if you chose to opt out, you would not be permitted to use any of the therapeutic or preventive
benefits that come from studies performed with data collected from the national patient identifier
system. These lost benefits would include safe and effective drugs, warnings
of emerging epidemics, information on side effects associated with your medications, biomarker
tests for preventable illnesses, and so on. Those who made no effort to help the system
would be barred from any of the benefits that the system provided. Would you reconsider
your refusal to cooperate, if you knew the consequences? Of course, this is a fanciful scenario,
but it makes a point.
- Jules Berman
key words: identification, confidentiality, privacy, medical identifier, NPI, national patient identifier, jules j berman, Ph.D., M.D.
Saturday, February 3, 2018
Paradoxes of Classification (and terrible Class definitions)
The formal systems that assign data objects to classes, and that relate classes to other classes, are known as ontologies. When the data within a Big Data resource is classified within an ontology, data analysts can determine whether observations on a single object will apply to other objects in the same class. Similarly, data analysts can begin to ask whether observations that hold true for a class of objects will relate to other classes of objects. Basically, ontologies help scientists fulfill one of their most important tasks; determining how things relate to other things.
A classification is a very simple form of ontology, in which each class is allowed to have only one parent class. To build a classification, the ontologist must do the following: 1) define classes (i.e., find the properties that define a class and extend to the subclasses of the class); 2) assign instances to classes; 3) position classes within the hierarchy; and 4) test and validate all the above.
The constructed classification becomes a hierarchy of data objects conforming to a set of principles:
- The classes (groups with members) of the hierarchy have a set of properties or rules that extend to every member of the class and to all of the subclasses of the class, to the exclusion of unrelated classes . A subclass is itself a type of class wherein the members have the defining class properties of the parent class plus some additional property(ies) specific for the subclass.
- In a hierarchical classification, each subclass may have no more than one parent class. The root (top) class has no parent class. The biological classification of living organisms is a hierarchical classification.
- At the bottom of the hierarchy is the class instance. For example, your copy of this book is an instance of the class of objects known as "books".
- Every instance belongs to exactly one class.
- Instances and classes do not change their positions in the classification. As examples, a horse never transforms into a sheep, and a book never transforms into a harpsichord.
- The members of classes may be highly similar to one another, but their similarities result from their membership in the same class (i.e., conforming to class properties), and not the other way around (i.e., similarity alone cannot define class inclusion).
Equus caballus Equus subg. Equus Equus Equidae Perissodactyla Laurasiatheria Eutheria Theria Mammalia Amniota Tetrapoda Sarcopterygii Euteleostomi Teleostomi Gnathostomata Vertebrata Craniata Chordata Deuterostomia Coelomata Bilateria Eumetazoa Metazoa Fungi/Metazoa group Eukaryota cellular organismsTaxonomists who view this lineage instantly grasp the place of domestic horses in the classification of all living organisms. The rules for constructing classifications seem obvious and simplistic. Surprisingly, the task of building a logical, and self-consistent classification is extremely difficult. Most classifications are rife with logical inconsistencies and paradoxes. Let's look at a few examples. In 1975, while touring the Bethesda, Maryland campus of the National Institutes of Health, I was informed that their Building 10, was the largest all-brick building in the world, providing a home to over 7 million bricks . Soon thereafter, an ambitious construction project was undertaken to greatly expand the size of Building 10. When the work was finished, building 10 was no longer the largest all-brick building in the world. What happened? The builders used material other than brick, and Building 10 lost its classification as an all-brick building, violating the immutability rule of class assignments. Apparent paradoxes that plague any formal conceptualization of classifications are not difficult to find. Let's look at a few more examples. Consider the geometric class of ellipses; planar objects in which the sum of the distances to two focal points is constant. Class Circle is a child of Class Ellipse, for which the two focal points of instance members occupy the same position, in the center, producing a radius of constant size. Imagine that Class Ellipse is provided with a class method called "stretch", in which the foci are moved further apart, thus producing flatter objects. When the parent class "stretch" method is applied to members of the Class Circle, the circle stops being a circle and becomes an ordinary ellipse. Hence the inherited "stretch" method forces members of Class Circle to transition out of their assigned class, violating the intransitive rule of classifications. Let's look at the "Bag" class of objects. A "Bag" is a collection of objects, and the Class Bag is included in most object-oriented programming languages. A "Set" is also a collection of objects (i.e., a subclass of Bag), with the special feature that duplicate instances are not permitted. For example, if Kansas is a member of the set of U.S. States, then you cannot add a second state named "Kansas" to the set. If Class Bag were to have an "increment" method, that added "1" to the total count of objects in the bag, whenever an object is added to Class Bag, then the "increment" method would be inherited by all of the subclasses of Class Bag, including Class Set. But Class Set cannot increase in size when duplicate items are added. Hence, inheritance creates a paradox in the Class Set. How does a data scientist deal with class objects that disappear from their assigned class and reappear elsewhere? In the examples discussed here, we saw the following:
- Building 10 at NIH was defined as the largest all-brick building in the world. Strictly speaking, Building 10 was a structure, and it had a certain weight and dimensions, and it was constructed of brick. "Brick" is an attribute or property of buildings, and properties cannot form the basis of a class of building, if they are not a constant feature shared by all members of the class (i.e., some buildings have bricks; others do not). Had we not conceptualized an "all-brick" class of building, we would have avoided any confusion.
- Class Circle qualified as a member of Class Ellipse, because a circle can be imagined as an ellipse whose two focal points happen to occupy the same location. Had we defined Class Ellipse to specify that class members must have two separate focal points, we could have excluded circles from class Ellipse. Hence, we could have safely included the stretch method in Class Ellipse without creating a paradox.
- Class Set was made a subset of Class Bag, but the increment method of class Bag could not apply to Class Set. We created Class Set without taking into account the basic properties of Class Bag, which must apply to all its subclasses. Perhaps it would have been better if Class Set and Class Bag were created as children of Class Collection; each with its own set of properties.
Thursday, February 1, 2018
Precision Medicine and the Reinvention of Human Disease (not just about genes)
If everything you know about Precision Medicine comes from the lay press, you may have an unrealistic notion of what's happening in this field. The news seems to stress the one gene -> one disease paradigm that is easy to understand, but largely irrelevant to all the common diseases that occur in humans.
The one gene -> one disease paradigm is this: the clinical expression of each disease is caused by a genetic mutation in a particular gene responsible for that particular disease, or a particular subtype of a disease, in a particular individual. By finding and targeting the gene responsible for an individual's disease, Precision Medicine will cure the patient.
This paradigm is short and sweet, and it is more or less true for a number of rare diseases; but it is wrong for just about every disease that occurs commonly in humans, and it serves to distract our attention from the medical revolution that Precision Medicine will bring.
The purpose of my new book, Precision Medicine and the Reinvention of Human Disease, discussed in previous blogs, is to explain how Precision Medicine is changing our fundamental understanding of the pathogenesis of disease (i.e., the biological steps that lead to the development of diseases), and how this new information is changing the way that we prevent, diagnose, and treat human diseases.
Precision Medicine is not about finding the right gene for the right patient. Precision Medicine is about finding the common events and metabolic pathways that account for the development and the expression of diseases; and using these insights to reduce the morbidity and mortality of disease in the population.
Google Books has a very good "look inside" for my book, and I hope that readers of this blog will take a few moments to see if they might be interested in the subject.
- Jules Berman
key words: precision medicine, jules j berman, Ph.D., M.D., disease biology, pathogenetic, monogenic, rare diseases, complex diseases, common diseases
Sunday, January 28, 2018
Precision Medicine and the Reinvention of Human Disease (a better definition)
We can define Precision Medicine as an approach to the prevention, diagnosis, and treatment
of disease that is based on a deep understanding of the sequence of biological events
that lead to disease. With this approach we are learning:
(1) that we can develop new drugs
that target specific steps in the development of disease;
(2) that drugs developed to interfere
with a cellular event or pathway may serve as effective treatments for those individuals
whose disease is driven by the pathway; and
(3) that a treatment effective for a subtype of
one disease may also be effective against other diseases that happen to be driven by the same
pathway.
This approach, based on learning the steps that precede the development of disease,
shifts the emphasis of Precision Medicine from finding unique treatments for unique
individuals to finding general treatments that are effective against precisely identified
biological processes, in whichever diseases those processes may occur. In the era of Precision
Medicine, every disease has a biological history, and every event in the history of the
disease is a possible target for prevention, diagnosis, or treatment. At this point, we can begin
to see the thread of a story that will unfold throughout my book, Precision Medicine and the Reinvention of Human Disease.
-Jules Berman
key words: precision medicine, definition, pathogenesis, steps in disease development, jules j berman
Saturday, January 27, 2018
Precision Medicine and the Reinvention of Human Disease (not just the genome)
If you believe the lay press, Precision Medicine involves sequencing a patient's genome and determining the proper treatment based on the individual's unique genetic attributes. The NIH (National Institutes of Health) seems to be encouraging this interpretation of the field. From the US National Institutes of Health comes the following description: "Precision Medicine is an emerging approach for disease prevention and treatment that takes into account people's individual variations in genes, environment, and lifestyle. The Precision Medicine Initiative will generate the scientific evidence needed to move the concept of Precision Medicine into clinical practice". An Advisory Committee to the NIH Director would include, under the mantle of Precision Medicine, "providing individual side-effect profiles of drugs, and preventative health care check-ups that include specific recommendations developed from interpreting an individual's genetic risk profile".
Between the millions of inter-individual variations in our genomes, the highly personalized lifestyle choices, and the differences in our environments, there seems to be plenty of uniqueness to spread around. It is easy to forget that our uniqueness as individuals often has much less to do with our diseases than does our sameness as members of the same species. Our sameness goes a long way toward explaining why humans seem to suffer from the same list of textbook diseases, regardless of their individualized genes and geography. Someone had to put the brakes on this epidemic of uniqueness.
Much to their credit, the National Research Council of the US National Academies tacked on the following caveat to the definition of Precision Medicine: "It does not literally mean the creation of drugs or medical devices that are unique to a patient, but rather the ability to classify individuals into subpopulations that differ in their susceptibility to a particular disease, in the biology and/or prognosis of those diseases they may develop, or in their response to a specific treatment". The Research Council wisely distinguished Personalized Medicine from Precision Medicine, by adding, "Although the term 'Personalized Medicine' is also used to convey this meaning, that term is sometimes misinterpreted as implying that unique treatments can be designed for each individual. For this reason, the Committee thinks that the term 'Precision Medicine' is preferable to 'Personalized Medicine'"
The National Research Council pointed out what should have been obvious from the start. We cannot provide individualized treatments, because treatments must be tested for safety and efficacy on groups of people. The best we can ever do is to assign patients to a group that has been fitted to a preapproved treatment. So where does this leave us?
More to follow in tomorrow's blog.
- Jules Berman
key words: precision medicine, genomics, individualized treatments, definition, jules j berman, Jules Berman Ph.D., M.D.
Friday, January 26, 2018
Precision Medicine and the Reinvention of Human Disease (from Preface)
Something has happened in the past two decades that has changed the way that modern biomedical scientist thinks about diseases. Because the changes in our perceptions have happened slowly, few of us have really taken notice of what it all means. The purpose of my latest book, Precision Medicine and the Reinvention of Human Disease, published January, 2018, is to show how advances in the field of Precision Medicine will forever change the way we understand and treat disease. Specifically, these advances are:
- Diseases develop in steps. Modern methodology has enabled us to dissect the biological events and metabolic pathways that ultimately lead to the expression of disease. We can no longer think in terms of the "cause" of a disease, because most diseases have multiple contributory causes, that act over time. [Glossary Pathway]
- Because disease development requires the successful completion of multiple, sequential steps, and because we can now observe some of these steps, Precision Medicine has given us multiple targets that we can attack, with the expectation of preventing diseases from developing, delaying the development of disease, or treating diseases that are driven by identifiable pathways.
- Because different paths of development may lead to the same set of clinical findings, diseases can be subtyped into classes according to the specific pathways that drive their biology. Hence, treatment can be precisely targeted to subtypes of diseases that were formerly indistinguishable from one another.
- Because diseases that appear to be unrelated might share biological pathways that can be successfully targeted by new classes of drugs, we can now prevent or treat a variety of diseases, using a drug that was specifically developed for one rare subtype of disease.
Thursday, January 25, 2018
Precision Medicine and the Reinvention of Human Disease (The Myth)
If you believe the hype, we are entering a new era of medicine in which each individual will receive unique treatment, determined by the sequence of his or her genome. This widely promulgated notion is simply ridiculous. There is no practical way to develop a unique treatment, test the treatment for safety and effectiveness, and titrate the correct dose, all for one person.
The terms "Precision Medicine" and "Personalized Medicine" have given us the false impression that medical science is moving away from off-the-rack remedies and is seeking treatments tailored to the individual. In actuality, science has always been about seeking generalization. When Isaac Newton watched an apple drop, he was not working on a new Law of Falling Apples. He was trying to understand the general laws of gravity and motion that applied to every object in the universe. When Charles Darwin spent 8 years studying barnacles, he was not trying to build a display collection of handsome barnacles for the national museum. He was developing a general theory of evolution that would apply to every living organism on earth. Likewise, when we study a specific pathway that is operative in a small percentage of cases of a rare tumor, accounting for perhaps a dozen patients worldwide, we expect that our findings will have general application to a wide variety of conditions.
Precision Medicine has very little to do with developing unique treatments. Like all medical research, Precision Medicine seeks to find general treatments that will be effective for the largest number of patients. The "Precision" in Precision Medicine refers to our ability to precisely diagnose rare diseases, and subsets of common diseases, that share a particular sensitivity to particular forms of treatment.
- Jules Berman
Tuesday, January 23, 2018
Precision Medicine and the Reinvention of Human Disease (Book Index)
In January, 2018, Academic Press published my book Precision Medicine and the Reinvention of Human Disease. This book has an excellent "look inside" at its Google book site, which includes the Table of Contents. In addition, I thought it might be helpful to see the topics listed in the Book's index. Note that page numbers followed by f indicate figures, t indicate tables, and ge indicate glossary terms.
A Abandonware, 270, 310ge Ab initio, 34, 48ge, 108ge ABL (abelson leukemia) gene, 28, 58ge, 95–97 Absidia corymbifera, 218 Acanthameoba, 213 Acanthosis nigricans, 144ge Achondroplasia, 74, 143ge, 354ge Acne, 54ge, 198, 220ge Acquired autoantibody disease, 133 Acquired Parkinsonism, 105ge, 128, 281 Acrodermatisis verruciformis, 26–27 Acrokeratosis verruciformis of Hopf, 23–24 Actinic keratoses, 33 Actinobacillus actinomycetemcomitans, 217 Actinomyces pyogenes, 217 Activated oncogene, 28, 34–35, 57ge, 222ge Acute anterior uveitis, 208 Acute flaccid myelitis, 204–205 Acutely transforming retroviruses, 46–47 Acute myelogenous/myeloid leukemia, 33–34, 97, 139, 156–157 Adaptive immunity evolved, 192 Adenosine deaminase, 46, 72, 80 Adrenocortical carcinoma, 73, 103ge Adult T-cell leukemia, 339 Adverse effect, 275, 352–353 Aflatoxin, 30, 182 and hepatocellular carcinoma, 30, 182 Age adjusted incidence, 338, 354ge Age related macular degeneration, 105ge, 138, 199 Aggregate disease, 80, 98ge Aging, 35–36, 70–71, 125–126, 234, 354 Agouti, 86–87 AIRE gene, 198 Albinism, 77–78, 81–82, 84 Alcohol, 128, 156, 159, 287 abuse, 128, 158 related neurodevelopmental disorders, 159 Allele, 70, 98ge, 158–159, 332–333, 347–348 Allelic heterogeneity, 71, 98ge Alpha1 antitrypsin deficiency, 82 Alpha particles, 166–167 Alpha-spectrin gene, 70 Alpha thalassemia, 83, 92 Alstrom syndrome, 122–123 Alternative RNA, 85, 98ge Alzheimer disease, 6–7, 70, 139, 233–234, 246, 327–328, 353 Amateur scientists, 329–330 Aminoglycoside, 128 induced hearing loss, 77 Amoebic encephalitides, 213 Amphotericin B, 128, 213 Amyloidosis, 83, 98ge, 200 Amyloid plaques, 126 Amyotrophic lateral sclerosis, 77, 282 Anaerobic conditions, 108ge Anal squamous carcinoma, 45 Anaphylactic shock, 133 Anaphylaxis, 133 Anaplasma phagocytophilum, 217 Anatomic abnormalities, 6–7, 166–167 Ancestral class, 184, 231 Aneuploid, 89, 89f Aneuploid cells, 49ge Aneuploidy, 47, 89f Angelman syndrome, 75, 86 Angiofollicular lymph node hyperplasia, 50ge Angiogenesis, 120, 138 Angioimmunoblastic lymphadenopathy, 55ge Angiopoietin, 139 Angiotensin converting enzyme inhibitors, 4 Animal model, 31, 33, 88, 170, 279, 351–354 Ankylosing spondylitis, 208 Anlagen, 243 Annotation, 264, 271, 308, 341 Anonymizing private and confidential medical data, 310 Anoxia, 91–92 Anterior segment mesenchymal dysgenesis, 53ge Anthers, 90 Antibasement membrane antigen, 132 Antibiotics, 190, 195–196, 210, 213 Antibody/antibodies, 21–22, 73, 126, 130–134, 139, 192, 197, 209, 299, 348–350 Anticipation, 86 Anucleate ovum, 254ge Anucleate red blood cell, 91 Aortic dissection, 142ge Apicomplexans, 184, 186 Aplastic anemia, 24–25, 95–96, 166 Apolipoprotein E (APOE) gene, 70 Apoptosis, 48–61, 73, 133–134, 197–200 Archaeans, 191 Archaeplastida, 186, 191–192 Aromatase inhibitors, 136–137 Arrhythmias, 135 Arrhythmogenic right ventricular cardiomyopathy, 331 Arrhythmogenic right ventricular dysplasia, 70 Artemis gene, 72 Arteriosclerosis, 171 Arthritis, 131–132, 134, 139, 197–198, 201, 208, 346, 349–350 Arthropod vectors, 202 Arylsulfatase, 121–122 deficiency, 121–122 Asbestos, 26–27, 29, 167–169, 279–280 Ash leaf spots, 102ge Aspergillus flavus, 182 Aspergillus fumigatus, 214 Aspirin, 124, 135 Asplenia/polysplenia, 72 Ataxia, 73, 83, 91, 128, 159 telangiectasia, 91 Atherosclerosis, 158, 171, 199 Atrial myxomas, 95–96 Atrioventricular conduction defects, 53ge ATRX gene, 92 Atypical hemolytic uremic syndrome, 199 Atypical intraductal hyperplasia, 32 Authentication, 273 Autism, 7, 138 Autoantibodies, 133–135, 137–138 Autoantibody disease, 130–134, 197 Autocoders, 283 Autocoding, 277, 282–283 Autocorrelation, 267 Autoimmune disease, 21–22, 131–134, 193, 197–198, 251 Autoimmune disorder characterized, 131 Autoimmune hemolytic anemia, 144ge Autoimmune lymphoproliferative syndrome (ALPS), 133–134, 197–198 Autoimmune polyendocrinopathy-candidiasisectodermal dystrophy, 198 Autoimmune thyroiditis, 201 Autoimmune variant, 73, 123–124 Autoinflammatory diseases, 197, 235 Autonomous growth, 46 Autophagy, 83 Autopsies, 81 Autopsy report, 36, 277 Autosomal dominant hearing loss, 104ge, 106ge Autosomal dominant polycystic kidney disease, 122–123 Autumn crocus (Colchicum autumnale), 200 Axonal neuropathy, 70 Azacytidine, 87 B Bacillary angiomatosis, 202, 210–211 Bacille Calmette-Guerin (BCG), 22–23 Bacillus B. globigii, 212 B. hoagii, 218 Bacteremia, 202, 213 Bacteroides B. fragilis, 214 B. vulgatus, 214 Bannayan-Riley-Ruvalcaba syndrome, 156, 173ge Bardet-Biedl syndrome, 72, 122–123, 157 Barr body, 85–86 Bartonella B. henhenselae, 210–211 B. quintana, 202, 217 Bartonella species, 202–203 Bartter syndrome, 136f Basal body, 72 Basal cell carcinoma, 158, 170 Base pairs (bp), 84, 86 Bastocystis, 213 B cell, 161, 192, 339, 346, 349–350 acute lymphoblastic leukemia, 160–161 lymphomas, 339, 349–350 BCR-ABL, 56ge Bcr/abl fusion gene, 28, 95–97, 251 BCR (breakpoint cluster region) gene, 58ge Beckwith-Wiedemann syndrome, 75, 86, 106ge Behcet disease, 99ge, 206 Benign tumor, 26–27, 50ge, 176ge Benzene, 166, 169 Bernard-Soulier syndrome, 59ge, 135 Bevacizumab, 138, 142ge Bilateral acoustic schwannomas, 56ge Bilateral progressive sensorineural hearing loss, 135 Bilateral retinoblastomas, 318ge Biliary atresia, 122–123 Bimodal age distribution, 52ge, 104ge, 292–293 Biomarker development, 252 Birth defects, 159, 335 Bisphossy jaw, 168–169 Bite infections, 213 BK virus, 339 Bladder catheters, 214 Bladder tumor, 95 Blast cells, 104ge Blastocystis, 213 Blast transformation, 104ge Blastula, 3, 51ge, 85, 235, 255ge, 335–336, 356ge Blau syndrome, 54ge, 199, 220ge Blended class, 205–206, 218ge, 246, 252ge, 258ge Blepharspasm, 350 Blistering disease, 123–124, 132 Blood cell lineages, 49ge Blood cells, 28, 82, 91, 131, 133–134, 137, 139–140, 164–166, 172, 197–198, 281, 295, 328 Blood clotting cascade, 164 Bloom syndrome, 50ge Boder sedgwick syndrome, 99ge Bone marrow failure, 24–25 Bone marrow necrosis, 30 Bone marrow stem cells, 49ge Bone marrow toxins, 166 Bootstrapping, 232, 287–288 Botox, 138, 171, 350 Bovine spongiform encephalitis, 219ge Bovine spongiform encephalopathy, 144ge BRAF, 290, 347–348 mutation, 347–348 V600E, 94–95 Brain tubers, 354 Branchiootorenal syndrome, 53ge BRCA gene, 28, 119, 126 Breakpoint cluster region (BCR) gene, 58ge Breast cancer, 32, 32f, 73–74, 95, 119, 126, 136–137, 250, 252, 299, 338, 347–348, 352 Bronchiectasis, 123, 289 Bronchioloalveolar carcinoma, 173ge Bronchoalveolar carcinoma, 173ge Bronchogenic carcinoma, 169 Bronchogenic lung cancer, 159, 167 Brucellosis, 200 Bruck syndrome, 142ge Brugada syndrome, 142ge Brugia malayi, 223ge Buerger disease, 159 Burgess shale reserves provided, 343 Burkitt lymphoma, 45, 161, 251, 339 Bypassing trials, 349 C Caffey disease (infantile cortical hyperostosis), 142ge CAG repeat, 71–72, 108ge, 300 Campylobacter pylori, 217 Cancer chemotherapy, 105ge, 157 death rate, 161, 245, 345 deaths, 31, 161, 167, 182, 245, 338, 340, 345 phenotype, 9ge, 46–47, 49ge progression, 87, 99ge Cancer-causing syndrome, 50ge Candidate biomarkers, 252 Candidate causal mutations, 94 Candidate gene, 79, 99ge, 129, 303, 331 approach, 99ge Carbapenem resistant Klebsiella pneumoniae, 38–40 Carcinogen, 29–31, 35, 50ge, 167, 169, 175ge, 182, 243, 347 Carcinogenesis, 9ge, 26–27, 30–31, 41, 46–47, 49–50ge, 54ge, 58ge, 73, 88–89, 167, 175ge, 338, 347 Carcinoid syndrome, 142ge, 144ge Cardiac conduction, 164 Cardiac rhabdomyoma, 102ge Cardiofaciocutaneous syndrome, 347–348 Cardiomyopathy, 101ge, 104ge, 128, 137, 209, 247–248, 331 Cargo disorder, 175ge Cargo receptor complex, 100ge Cargo vesicle, 100ge Carney complex, 95–96, 99ge, 103ge Carney syndrome, 50ge, 99ge Carotid body chemoreceptor cells, 81 Carriers, 28, 32–33, 50ge, 78, 96–97, 107ge, 182, 194–195, 219ge, 332–336, 339 Case studies, 99ge Castleman disease, 45, 50ge, 331 Categorical data, 291 Catheter, 214, 219ge Cattle, 332–333 Causality, 6, 17–61, 356–357ge paradoxes, 17–25 Cause of death error, 311ge CCR5 coreceptor, 172 Cd1a, 139 CD20 inhibitors, 346, 349–350 Ceased and liver tumor, 47 Celiac disease, 208 Cell death, 3, 48, 49ge, 61ge, 80, 91, 99ge, 133–134, 197–198, 254ge Cell death rates, 254ge Cell division, 3, 21, 56–58ge, 60–61ge, 90, 190–191 Cell free media, 203 Cell junctions, 193 Cell suicide, 48, 49ge Cell type, 9ge, 19–20, 26, 30–31, 35, 42–43, 48, 49ge, 51–52ge, 56–58ge, 60ge, 71, 80, 84–85, 89–90, 92, 101ge, 107–108ge, 120, 129–130, 175ge, 219ge, 222ge, 278, 281 Cellular differentiation, 89, 100–101ge Cellular hypoxia, 81 Cellular pathway, 4, 120, 128–130, 164, 169–170, 175ge, 199 Cellulitis, 29, 213 Centers for Disease Control and Prevention (CDC), 38–40, 306–307 Cerebellar ataxia, 99ge, 128 Cerebellum, 102–103ge, 156, 159, 174ge Cerebrospinal fluid, 79 Cervical cancer, 32, 338–340, 358ge Chagas disease, 187–188, 194–195, 219ge, 339 Channel defects, 121 Channel disorders, 142ge Channelopathies, 9–10ge, 124, 142ge Charcot-Marie-Tooth disease, 51–52ge, 70, 175ge, 331 Chediak-Higashi syndrome, 10ge, 199 Chemodectomas, 81 Chemokine, 76, 100ge, 172 Chemoreceptor cell hyperplasia, 81 Chernobyl, 169 Cherubism, 199 Chicago heat wave, 295–296 Chikungunya virus, 219ge, 223ge Childhood cancer, 27, 49ge, 161, 343, 345 Childhood thyroid cancer, 169 Chimeric Antigen Receptor for T cells (CAR-T) therapy, 161–162 Chimeric receptor, 161–162 Chimney sweeps, 166 Chimpanzee’s genome, 75–76 Chitin, 217, 242 Chlamydia trachomatis, 208 Chloramphenicol, 166 Chloroplasts, 191–192, 219ge Cholangiocarcinoma, 30, 60ge, 166–167, 339 Chorioadenoma destruens, 255ge Choriocarcinoma, 108ge, 161, 220ge, 251, 254–255ge, 257–258ge Chromatin remodeling complex, 85, 89 Chromosomal aberration, 156–157 Chromosomal anomalies, 94, 335 Chromosomal instability, 49ge Chronic myelocytic leukemia, 58ge, 161 Chronic myelomonocytic leukemia, 56ge, 104ge Chronic obstructive pulmonary disease (COPD), 98ge, 158–159, 246, 253ge Chronic recurrent multifocal osteomyelitis/synovitis, 198 Chryseobacterium meningosepticum, 217 Churg-Strauss syndrome, 206 Chytrids, 241–242 Cigarette smoking, 156, 173ge Cigarette use, 158 Ciliated epithelia, 9ge Ciliopathies, 9ge, 122–123, 124f Circulating proteases, 82 Cirrhosis, 58ge, 82–83, 100ge, 126, 128–130, 158–159, 164–165t, 197 Cis acting, 100ge, 108ge CJD prion, 144ge C-KIT, 56ge, 103ge, 140 Clade, 253ge Cladistics, 253ge, 255ge Class Apicomplexa, 184 Class Archaeplastida, 191–192 Class assignment, 187, 205, 218ge, 221–222ge, 243–244, 252–253ge, 311ge Class blending, 218ge, 244–247, 252ge Class Crianata, 219ge Classification, 5, 10ge, 59–60ge, 93–109, 183–184, 185f, 186–187, 206, 229–232, 239–244, 253ge, 269, 311ge, 341 Classifier algorithms, 243–244, 253ge Class Mimiviridae, 221ge Class properties, 184, 189, 231, 234–235, 256ge Clear cell carcinoma, 106ge Clinical trial, 5, 8ge, 136–137, 162, 239, 244, 295, 343–350 Clinorchis sinensis, 60ge Clonal disorder, 105ge Clonal expansion, 31, 56ge, 102ge, 105ge, 107ge, 134, 248–249 Cluster analysis, 253ge Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology, 335–336 Coagulopathies, 235 Coding mutations, 99ge, 119, 126, 137, 140, 158–159, 281 regions, 158–159 Codon, 56ge, 106ge, 287–288, 311ge Coelomic, 237, 243 Colchicine, 200 Collagen disorder, 142ge Collagenopathy, 128, 142ge, 164 Combined DNA Index System (CODIS), 265 Commensal organism, 214 Common ancestor, 102ge, 105ge, 187, 221–222ge Comparing genome sequences, 265 Complement disorders, 199 Complement regulatory diseases, 198 Completeness, 230, 272, 276 Complex disease, 54ge, 58ge, 173ge, 201, 220ge, 352 Complexity barrier, 299–300 Conduction disorders, 164 Congenital anomaly, 51ge, 94, 355ge Congenital disorder, 24–25, 51ge, 58ge, 164, 173ge, 175ge Congenital dyserythropoietic anemia, 254ge Congenital heart defects, 122–123 Congenital hyperinsulinism, 142ge Congenital tumor, 155–156 Conserved gene variants, 157–158 Contig disease, 355ge Contiguous gene deletion syndrome, 355ge Control population, 298, 358ge Control samples, 174ge Control subjects, 99ge, 281 Converged pathway, 137, 140, 239 Convergence, 4–5, 8ge, 73–74, 117–145, 187, 200, 221–222ge Convergent disease, 135–145, 340, 346, 350 COPD. See Chronic obstructive pulmonary disease (COPD) Copy neutral, 109ge Copy number, 47, 51ge, 57ge, 102ge, 222ge Coronary artery disease, 38, 143ge, 182 Coronary artery thrombosis, 38 Corpora amylacea, 126 Corpus callosum, 159 and alcoholism, 159 Correlation, 96, 107ge, 121, 267, 315ge, 352 distance, 311ge Cost of curing curable disease, 141 Cowden syndrome, 50ge, 95, 100ge, 102ge, 156, 173–174ge Cowdry bodies, 280f, 281 Coxsackie virus, 209 CpG islands, 84, 87, 100ge, 109ge CpG methylation patterns, 100ge CpG sites, 84, 90, 100ge Cranioectodermal dysplasia (Sensenbrenner syndrome), 122–123 Creutzfeldt-Jakob disease, 144ge, 219ge Cri du Chat, 104ge CRISPR technology. See Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology Crohn disease, 54ge, 99ge, 199, 201, 220ge Curator, 302, 307–308, 311ge Curse of dimensionality, 296, 311ge Cutis laxa, 72, 134, 289, 354ge Cyanobacteria, 191–192, 219ge Cyclooxygenase–2, 24 Cyclospora, 184, 219ge Cyst, 104ge, 213, 216–217 Cystic fibrosis, 71, 98ge, 141, 142ge, 160, 334, 351, 356ge Cytokine signaling, 83, 198 disorders, 199 Cytokine storm, 140, 352–353 Cytomegalovirus, 182, 222ge, 281 infection, 280f Cytotoxic agents, 87, 105ge Cytotoxic lymphocytes, 143ge Cytotrophoblasts, 193, 238 D DARC, 172 Darier disease, 24, 26–27 Dark data, 311ge Data mining, 230, 355ge object, 9–10ge, 13ge, 143ge, 243–244, 253–258ge, 264–271, 273–275, 285–286, 290–291, 298, 311–314ge, 316–318ge, 355ge, 357–358ge readers, 341 repurposing, 312ge, 355ge resource, 122–123, 252, 254ge, 271–272, 284, 286, 292–293, 341, 352 scrubbing, 307, 312ge, 355–356ge sharing, 302–318, 312ge, 343, 349 triple, 267 Death certificate, 13ge, 38–40, 39f, 311ge, 339 Dedifferentiation, 101ge Deficiency of the interleukin-1 receptor antagonist, 198 Deidentified record, 275, 308 Dengue virus, 223ge De novo mosaic disease, 336 De novo mutation, 12ge, 24, 51ge, 57ge, 101ge, 107ge, 331–332, 334–336, 356ge Dentatorubropallidoluysian atrophy, 108ge Deoxyadenosine deaminase deficiency, 80 Deoxycoformycin, 80 Dermal bone, 254–255ge Dermatofibroma, 45 Developmental disorder, 7, 75, 105ge, 139, 154–155t, 156 Diagnostic and Statistical Manual of Mental Disorders (DSM), 7–13 Diethylstilbestrol fulfill, 30–31 Differentiation, 55ge, 80, 89, 100–101ge, 108ge, 243, 349–350 Digenic disease, 105ge, 173ge DiGeorge syndrome, 104ge, 131 Dilated cardiomyopathy, 70, 95, 122–123, 128, 143ge Dimensionality, 253ge, 296, 312ge, 356ge Discordant diagnoses, 247–248 Disease convergence, 4–5, 8ge, 73, 117–145, 187, 200, 221–222ge Disease pathway, 3, 40–44, 105ge, 142–145, 163, 170, 349–350, 353 Diseases-in-waiting, 205–210 Disease variants, 73, 78, 123–124, 132, 303, 331–332 Distal myopathy, 98ge, 279 Diuretics, 121, 136 DNA crosslink repair, 42, 51ge DNA repair, 22, 34, 41–42, 48, 49ge, 51ge, 61ge, 72, 80, 84, 91, 99ge, 144ge, 164 DNA replication, 51ge, 144ge Donovania granulomatis, 217 Double stranded DNA, 186–187, 221ge Down syndrome, 52ge Dravet syndrome, 142ge, 303 Driver pathway, 9ge, 170, 174ge Drug-induced methemoglobinemia, 128 DSM. See Diagnostic and Statistical Manual of Mental Disorders (DSM) Ductal carcinoma in situ (DCIS), 32, 32f, 95 Duffy blood group antigen, 172 Dynein arms, 123 Dyserythropoiesis, 250, 254ge Dyslipidemias, 164, 172 Dysmorphic facial development, 33–34 Dysmorphism, 121–122, 127, 156, 170, 234 Dysplasia, 51ge, 53ge, 70, 104ge, 122–123, 136f, 156–157, 175ge, 358ge Dysplastic gangliocytoma, 102ge, 156 Dysplastic nevi, 33, 95 Dysregulations, 88, 106ge, 235 Dystrophic epidermolysis bullosa, 134 Dystrophin, 122 E Early detection, 248–249, 251–252 Eaton lambert syndrome, 144ge Ebola virus, 210 Ectoderm, 58ge, 61ge, 88, 101–102ge, 104ge, 235–238, 255ge Edematous placental villi, 220ge Eearly onset sarcoidosis, 54ge, 220ge Ehlers-Danlos syndrome, 142ge Electronic health record, 341 Electronic medical record, 272–273, 276, 340 Ellis van Creveld syndrome, 122–123 Embryo, 3, 30–31, 34, 54ge, 59ge, 85, 92, 103ge, 107ge, 235, 238, 252, 254–255ge Embryogenesis, 81, 86, 103ge, 255ge Embryonal carcinoma, 161, 238, 255ge Emery-Dreifuss muscular dystrophy, 330 Emphysema, 82–83, 134, 158–159, 164–165t Encapsulation, 308, 310, 312ge Encephalitis lethargica, 206 Encephalitozoon intestinalis, 217 Enchondral bone, 238, 254–255ge Encryption, 276, 312ge Endocarditis, 202–203, 213, 220ge Endoderm, 58ge, 61ge, 101ge, 104ge, 142ge, 235–238, 252ge, 255ge Endodermal/Ectodermal neoplasms, 236 Endometrial carcinoma, 156 Environmental disease, 22, 83, 208 Environmental factors, 11–12ge, 24, 97, 119, 121, 127, 129, 158, 173, 173ge Eosinophilic granulomatosis, 206 Epidermis, 30, 48, 53ge, 58ge, 60ge, 73, 101ge, 107ge, 123–124, 132, 242 Epidermolysis bullosa, 8ge, 70, 73, 123–124, 134 Epigenetic instability, 87, 108ge Epigenome, 47–48, 51ge, 84–93, 89f, 100–101ge, 103ge, 108ge, 130, 154–155t Epigenomic disease, 85, 90, 92 Epigenomics, 47–48, 84–93, 100–101ge, 129–130, 154–155t, 252ge Epistasis, 6, 9ge, 42–43, 57ge, 144ge Epithelial and non-epithelial tumors, 243 Eponymous disease, 45, 52ge Epstein-Barr virus, 45, 55ge, 79, 140, 251, 339 Erasure, 85, 91, 103ge Esophageal cancer, 159 ETV6-NTRK3 fusion, 250 Eugenics, 19, 331–337 Eukaryote, 55ge, 57ge, 182–183, 191–192, 205, 213, 219ge, 241, 354 Evolution, 48, 190–193, 230–231, 327–328, 343, 354 Evolutionary taxonomy, 184 Evolve, 8ge, 41–42, 60ge, 191–192, 306 Exceptional responders, 275, 295, 348–349 Exceptional responder trials, 348 Exome sequencing, 78–79, 98 Exon, 98ge, 101ge, 106ge Exotic disease, 181, 219ge Expressed genes, 109ge, 292 eXtended Markup Language (XML), 264–265, 317ge EYA4 gene, 95 F Facial angiofibromas, 102ge Factor VIII, 56ge, 100ge, 134, 172 Facultative intracellular organism, 190–191, 220ge Fair use, 307, 312ge Familial aneurysm disorders, 142ge Familial cold autoinflammatory syndrome, 54ge, 198–199, 220ge Familial cold autoinflammatory syndrome-2 (Guadaloupe periodic fever), 199 Familial dilated cardiomyopathy, 70, 95 Familial HLH, 199 Familial hypercholesterolemia, 56ge, 59ge, 164–165t, 171 Familial hypocalciuric hypercalcemia type, 134 Familial mediterranean fever, 54ge, 198, 200, 220ge Fanconi anemia, 42, 49–51ge Father’s sperm, 11ge Ferruginous bodies, 279–280 Fibrochondrogenesis, 70 Fibromyalgia, 206 Fibrosing disorders, 199 Fibulin, 72 Filaria, 208, 218 First analyses, 303, 310 Flagellum, 199, 241–242 Flattening, 48, 341, 354 Flawed data, 307–308 Fleas, 202 Flu epidemic, 294, 332–333 Fluke, 48, 182, 339 Folic acid supplementation, 121 Food and Drug Administration, 141, 160–161, 346 Foreign antigen, 21–22, 192, 218ge Forme fruste, 165, 174ge Founder effect, 332–333, 356ge Founder’s mutation, 356ge Fourier series, 288, 357ge Fragile x syndrome, 99ge, 108ge, 355ge Free-lance data analysts, 343 Frequency, 34–36, 40, 57–58ge, 106–107ge, 125–127, 131, 155, 170, 189, 291, 292f, 300, 310, 318ge, 357ge distribution, 291 Freshwater, 194 Friedreich ataxia, 83, 99ge, 108ge, 143ge Frontotemporal dementia, 77, 281, 354ge Fungemia, 212 G GAA repeat, 83 Gain-of-function, 119 Gamete, 102–103ge, 174ge, 238, 255ge, 336 Gastric maltomas, 49ge Gastrointestinal stromal tumor (GIST), 103ge, 140 Gastrulation, 236–238 Gaucher disease, 280, 334 Gaussian curve, 358ge Gaussian distribution, 288, 291 Gene duplication, 105ge Gene editing, 327–328, 335–336 Gene pool, 18, 35–36, 119, 157–158, 183–184, 190–191, 331–336 Gene sequence, 42, 161, 187, 204–205, 290 Gene silencing, 86–87, 336 Gene therapy, 46, 160–161 Genetically engineered mouse (GEM), 52ge Genetic disease, 11ge, 22, 69–70, 120, 160, 208, 235, 335 Genetic heterogeneity, 8ge, 71, 74, 101ge, 103ge, 144ge Genetic instability, 47, 49ge, 87–88, 89f, 92–93, 95, 99ge, 102ge, 175ge, 357ge Genetic mosaicisms, 336 Genetic mutation, 2, 7ge, 11ge, 24–25, 72, 74–75, 80, 85, 90, 97, 118, 125, 127, 139, 145ge, 171, 175ge, 303 Genetic testing, 71 Genome testing, 97 Genome-wide Association Study (GWAS), 174ge Genotype, 9ge, 23, 52ge, 60ge, 97, 99ge, 103ge, 144ge, 157, 175ge, 183, 215 Geriatric disease, 233 Germ cell(s), 52ge, 55–57ge, 59ge, 61ge, 102–103ge, 107ge, 155–156, 174–175ge, 235, 238, 251, 255ge, 290, 336, 339 of body, 52ge line, 255ge, 336 neoplasms, 238 origin, 238, 290 tumors, 103ge, 155–156, 238, 251, 339 Germinomas and seminomas, 175ge, 238, 255ge Germ layer, 85, 104ge, 236–238, 242–243 Germline, 7ge, 25, 27–28, 33–34, 49ge, 51–52ge, 54ge, 60ge, 75–76, 80–82, 85–86, 97, 101ge, 103ge, 107ge, 109ge, 119, 126, 128, 130, 156, 220ge, 255ge, 313ge, 335–336 Germline mutation, 7ge, 25, 27, 33–34, 49ge, 51–52ge, 75–76, 80–82, 102ge, 107ge, 119, 130, 156 Gerstmann Straussler Scheinker Syndrome (GSS), 144ge Gestational mole, 220ge Gestational trophoblastic disease, 255ge Giant cell (temporal) arteritis, 206 Gilbert syndrome, 57ge GIST. See Gastrointestinal stromal tumor (GIST) Glioblastoma, 138, 156 Gluten sensitive idiopathic neuropathies, 206 Glycosylation disorder, 58ge, 164, 173ge, 175ge Gnathostomes, 192–193, 218ge Golgi bodies, 41 Goodpasture syndrome, 132–133 Gorlin syndrome, 170, 175ge Gout, 124, 198–201, 351–352 Granulocyte/macrophage colony stimulating factor (GM-CSF), 137–138, 346 Graves’ disease, 131–132 Grawitz tumor, 282–283 Griscelli syndrome, 175ge, 199 Group A streptococcus infection, 21–22, 203 Gulf War syndrome, 206 GWAS. See Genome-wide Association Study (GWAS) H HACEK, 203, 213, 220ge Haemophagocytic lymphohistiocytosis, 140, 199 Hairy cell leukemia, 55ge, 161 Hallermann Streiff syndrome, 206 Hamartin, 72, 103ge, 139, 354ge Hamartoma, 56ge, 72, 100ge, 102ge, 138–139, 156, 174ge, 234, 354 Haploid, 86, 102ge human genome, 287 Haploinsufficiency, 75 Haplotype, 86, 102ge Hashimoto thyroiditis, 134 Healthcare institutions, 316ge Hearing loss, 70, 82, 104ge, 106ge, 123, 128, 135, 173ge Heat related deaths, 295–296 Heavy legs, 206 Helicobactor pylori infection, 49ge Hematopoietic tissue, 166, 254ge Hemochromatosis, 128, 143ge Hemoglobin, 42, 56ge, 105ge, 107ge, 119, 143ge, 160, 163, 195–196, 334–335, 354ge synthesis, 195–196 Hemolytic anemia, 133–134, 144ge, 197–198 Hemolytic uremic syndrome, 135, 199 Hemophagocytic lymphohistiocytosis, 99, 199 Hemophilias, 164, 235 HEMPAS, 254ge Henoch schonlein purpura, 206 Hepatic angiosarcoma, 166–167 Hepatitis B virus, 339–340 Hepatitis C virus, 339 Hepatocellular carcinoma, 30, 47, 52ge, 58ge, 83, 166–167, 182, 339–340 Herceptin, 348 Hereditary angioedema, 126, 135 Hereditary hemorrhagic telangiectasia, 138 Hereditary inclusion body myopathy, 98ge Hereditary leiomyomatosis, 79 Hereditary nonpolyposis colorectal cancer syndrome (HNPCC), 143ge Hereditary thrombocythemia, 98ge, 105ge, 139, 165 Hermansky-Pudlak syndrome, 175ge, 199 Herpes simplex infections, 194–195, 281 Heterochromasia iridum, 289 Heterokont, 213 Heterotaxy, 72, 105ge, 123 Heterozygosity, 54ge, 103ge, 109ge High blood pressure, 44, 136 Hispaniola, 189, 196 Histiocytic medullary reticulosis, 103ge HIV, 100ge, 128, 172, 196, 199, 221ge and AIDS, 210–211, 219ge Hodgkin lymphoma, 45, 52ge, 70, 161, 292–293, 293f, 357ge Holt-Oram syndrome, 61ge, 76, 145ge Homolog 1, 130 Homologous genes, 184 Homologs, 105ge, 354 Homology, 214, 253ge Homunculus, 3 HTLV-1, 339 HTT gene (and CAG repeat), 71–72 Human malaria, 215 Human subject, 275–276, 294–295, 301, 307–308, 310, 345–346, 348, 356ge Huntingtin protein, 71–72 Huntington disease, 71–72, 99ge, 103ge, 108ge, 300, 354ge Hurler disease, 282 Hydatidiform mole, 198–199 Hydrops-ectopic calcification-‘moth-eaten’ (HEM), 96 Hydrops fetalis, 96, 131 Hyperbilirubinemia, 57ge Hypercholesterolemia, 127, 171–172 Hyperimmunoglobinemia D with periodic fever syndrome, 198 Hyperimmunoglobulin D, 54ge, 220ge Hypermethylation, 86–87, 130 Hypermutate, 134 Hypernephroma, 282–283 Hypersurveillance, 327–329 Hypertension, 24–25, 121, 128, 136–137, 136f, 139, 158, 162, 165, 174ge, 334 Hyperthermia, 142ge, 144ge Hypertrophic osteoarthropathy, 10ge Hypocalciuric hypercalcemia, 284 Hypomethylating agents, 86–87, 91 I ICD. See International Classification of Disease (ICD) Ichthyosis, 104ge Identification, 143ge, 160, 204, 234, 240–241, 253ge, 265, 271–277, 286, 308, 313ge, 338 Identifier, 13ge, 174ge, 253ge, 265, 355ge IL-1-beta activation disorders, 198 Imatinib, 4, 140–141, 161, 346 Immediate cause, 37–38 Immune deficiency, 194, 222ge syndromes, 192–193, 197, 218ge Immunocompromised individuals, 194, 213 Immunodeficiency, 46, 72, 76, 79–80, 84, 98ge, 332–333, 352 Immunosuppressed individuals, 45 Immutability, 270–271, 273 Imprinting, 86 Inactivated x chromosome, 279 Incidental finding, 213 Inclusion bodies, 279–281 Incomplete dominance, 144ge Indexing, 277, 281 Infectious disease, 7ge, 34, 36, 50ge, 53ge, 154, 181–190, 194–196, 202–204, 209–211, 213–214, 216, 219ge, 222ge, 231, 233–234, 251, 339, 352, 356ge Inflammasome, 198, 200, 207 Inflammasomopathies, 198 Inflammatory disease, 54ge, 94, 139, 196–201, 220ge, 251 Inflammatory myofibroblastic tumor, 346 Inflammatory pathway, 139, 196–197, 200–201 Inflammatory response syndrome, 8ge Information is release, 305 Informed consent, 346 Inherited dilated cardiomyopathy, 171 Inherited retinoblastomas, 313ge Initiation, 45, 50ge, 54ge, 101ge, 145ge Initiation factor, 56ge, 145ge Innate immune system, 138, 197–201 Inscrutable genes, 69–78 Institutional Review Boards (IRBs), 275–276, 307, 346 Intermediate cause, 37–38 Internal body spaces, 237 International Classification of Disease (ICD), 233–234 Interoperability, 282, 306 Interpretation errors, 300 Interstitial cystitis, 206 Intracellular, 134, 190–191, 195, 199–200, 217, 220–222ge, 279 organisms, 195 Intraductal hyperplasia, 32 Intraflagellar transport, 123 Intrinsic factor, 135 Intrinsic immunity, 281 Introns, 83 Introspection, 269–270 IRBs. See Institutional Review Boards (IRBs) Irreproducible, 6, 216, 218ge, 252ge, 298–300, 309 Irreversible, 126, 275–276 Irritable bowel syndrome, 206, 213 J JAK2, 105ge, 139–140, 165 JAK2 mutation, 56ge, 140, 165 JAK2V617F, 140 Janus kinase, 72 Jeune chondrodysplasia syndrome, 122–123 Joubert syndrome, 122–123 K Kallman syndrome, 98ge, 104ge Kaposi sarcoma, 45–46, 50ge, 210–211, 293, 339 Karyopyknosis, 49ge Karyotype, 89f, 103ge Kashin-Beck disease, 206, 209 Kawasaki disease, 206 Kelley-Seegmiller syndrome, 105ge Keratoacanthoma, 45, 49ge, 54ge Kingella kingae, 203, 220ge Klebsiella granulomatis, 217 Knockout mice, 27, 54ge, 128, 143ge, 352 Koch’s postulates, 201–205, 352, 356ge Koilocytosis, 280f Korean War, 286–287 Kupffer cells, 166–167 L LAMA4 gene, 95 Lamellar inclusions, 137 Lamina propria, 203–204, 208 Lamin B receptor, 96 Lamin gene, 330–331 Large follicular center cell (diffuse histiocytic) lymphoma, 161 Lassa fever, 219ge Latency, 29–30, 46–47, 54ge Lead-induced encephalopathy, 128 Leber congenital amaurosis, 122–123 Legacy data, 270, 273, 306, 314ge Leishmaniases, 194–195, 342 Leishmaniasis, 154, 187–189, 219ge, 223ge Leri-Weill dyschondrosteosis, 53ge Lesch-Nyhan disease, 351–352 Lethal acantholytic epidermolysis bullosa, 70 Lethal genotypes, 144ge Lethal junctional epidermolysis bullosa, 6, 70 Leukemia, 4, 9ge, 28, 33–35, 46, 49ge, 55–56ge, 58ge, 73, 87, 95–97, 103–104ge, 139–141, 142ge, 155–157, 160–162, 166, 233–234, 251, 339, 346, 349–350, 354ge Lewy bodies, 126, 279 dementia, 279 Lichen sclerosus, 206 Liddle syndrome, 24–25, 136f, 165 Li-Fraumeni syndrome, 49–50ge, 73, 103ge Ligneous conjunctivitis, 79, 354 Limb malformation, 75, 168 Lineage, 9–10ge, 49ge, 51–52ge, 55–56ge, 84–85, 88, 100–103ge, 105ge, 107–108ge, 131, 185f, 230–232, 235, 242–243, 252–253ge, 255–257ge, 314ge, 318ge, 358ge Lipodystrophy, 70–71, 172, 330–331 Lipopolysaccharide, 353 Liver cancer, 28, 47–48, 52ge, 159, 251, 340 LMNA (Lamin A/C), 70–71, 331 LMO2, 46 Locus heterogeneity (LOH), 71–72, 101ge, 103ge, 120, 141 Long branch attraction, 187, 221–222ge Long noncoding RNA, 106ge Loss-of-function, 98–99ge, 118, 158–159, 197–198 Lou Gehrig disease, 282 Louis-Bar syndrome, 99ge Low penetrance, 27, 50ge LRRK2 gene mutation, 164–165t, 171 LRRK2 protein kinase, 171 Lubeck disaster, 22 Lymphoma, 28, 45–47, 49–50ge, 52ge, 55ge, 88, 103ge, 139, 155–157, 161, 251, 292–293, 293f, 339–340, 346, 349–350, 356–357ge Lymphoproliferative disease, 45, 55ge Lymphoproliferative disorder, 50ge, 56ge Lynch cancer family syndrome, 50ge Lynch syndrome, 119, 143ge Lytico-Bodig disease, 206 M Machine translation, 255ge, 282–283 Macrophage, 23, 54ge, 137–138, 140, 195, 198–199, 201, 203–204, 220ge, 280–281, 346 activation disorders, 199 Mad hatter disease, 168 Majeed syndrome, 54ge, 198, 220ge Major histocompatibility complex, 72 Malakoplakia, 281 Malaria, 107ge, 169, 172, 182, 184, 195–196, 215, 219ge, 223ge, 244–245 Malassezia furfur, 217 Malignant fibrous histiocytoma (MFH), 218ge, 252ge Malignant phenotype, 28, 47–48, 50ge, 55ge, 87, 99ge, 105ge, 107ge, 175ge Malignant transformation, 26–27, 238 Malnutrition, 219ge, 222ge MALToma, 30, 48, 357ge Maltomas, 49ge, 55ge Mantle zone, 1 Manual coding, 283 Marchiafava-Bignami disease, 159 Martsolf syndrome, 175ge Materia medica, 200 Maternal lineage, 55ge Mathematical models, 356ge Maturity onset diabetes of the young (MODY), 76, 96–97 Mayaro fever virus, 219ge McKusick-Kaufman syndrome, 122–123 Meckel-Gruber syndrome, 122–123 Mediterranean anemia (thalassemia), 200 Medullary, 81, 103ge Medullary thyroid carcinoma, 237, 255ge Medulloblastoma, 103ge Melanoma, 26–27, 33, 55ge, 94–95, 103–104ge, 107–108ge, 237, 288 MEN2 (multiple endocrine neoplasia-2), 256ge Mendelian disease, 104ge, 131 Mendelian inheritance, 104ge, 131–132, 144ge, 154 Menetrier disease, 53ge Merkel cell carcinoma, 339 Mesenchymal cells, 242–243 Mesoderm, 58ge, 60–61ge, 88, 101ge, 104ge, 158, 235–238, 242–243, 255ge Mesothelioma, 26–27, 29, 126, 167–168, 339 Metabolic pathway, 24, 117, 120, 125, 159, 191, 235, 346, 348 Metabolic syndrome, 158, 174ge Metadata, 264, 267–270, 286, 311ge, 316ge Metastasis, 9ge, 144ge, 221ge, 251, 255ge Metazoa, 230, 255ge Methemoglobinemia, 128 Methotrexate, 128 Methylating agents, 86–87, 91 Methylation, 75, 84, 86–87, 90–91, 100–101ge, 103ge inhibitors, 91 Methylmalonic acidemia, 128 MFH (malignant fibrous histiocytoma), 218ge, 252ge MGUS (monoclonal gammopathy of undetermined significance), 31, 55ge, 248–249 Microarray, 13ge, 336, 342, 357ge Microdeletion disease, 104ge Microphthalmia-, 53ge, 61ge, 82, 145ge MicroRNA, 85, 91–92, 104ge, 106ge Microsatellite, 57ge, 98ge, 143–144ge instability, 119, 140, 144ge Microscopic polyangiitis, 207 Microthrombotic disorder, 125 Miller syndrome, 128 Milroy disease, 75, 96–97, 120 Mimics of common diseases, 129, 131, 248 Mimics of rare inherited disease, 131 MiRNA, 104ge Misfolded proteins, 98ge, 144ge Mismatch repair, 42, 51ge, 130, 140, 143–144ge pathway, 130 Mitochondrial DNA, 73, 77 Mitochondrial myopathy, 128 Mitochondriopathic deafness, 128 Mitochondriopathies, 84, 104ge, 164 Mitosis, 55–56ge, 109ge Modeling algorithms, 357ge MODY (maturity onset diabetes of the young), 76, 96–97, 121, 164–165t Monkeypox virus, 219ge Monoclonal gammopathy, 31, 50ge, 55ge, 248–249 Morgellons disease, 207 Mortimer disease, 207 Motor neuron disease, 104ge, 279 Muckle-Wells syndrome, 54ge, 198, 220ge Mucolipidosis, 142ge Muir-Torre syndrome, 50ge Multicentric Castleman disease, 50ge Multiclass classification, 230, 255ge Multiclass inheritance, 50ge, 256ge Multifactorial disease, 103ge Multiple basal cell carcinoma, 175ge Multiple endocrine neoplasia, 256ge Multiple myeloma, 31, 55–56ge, 248–249, 249f Multiple sclerosis, 197, 201, 349–350 Multipotent stem cell, 56ge Multi-step disease, 29–30 Multistep pathogenesis, 12ge, 205 Muscular dystrophy, 53ge, 56ge, 70, 122, 175ge, 330 Muscularis propria, 265 Mutagen, 56ge Mutation, 2, 23, 69–70, 118, 156, 187, 250, 281, 329 Mutation rate, 336, 357ge Mutator phenotype, 156–157, 175ge Myalgic encephalomyelitis, 346, 349–350 Myasthenia gravis, 126, 133, 142ge, 197 MYC, 47–48, 95 Myelodysplastic syndrome, 104ge, 156–157, 250 Myelofibrosis, 56ge, 139, 165 Myeloproliferative disorders, 33–34, 56ge, 60ge, 104ge, 124, 139–140, 165 Myeloproliferative syndrome, 48ge Myofascial pain syndrome, 207 Mytotonic dystrophy, 108ge Myxomatosis, 350–351 N Naegleria encephalitis, 194, 213 Naegleria fowleri, 194, 213 National Academies of Sciences, 1 National patient identifier, 276–277, 314ge Natural selection, 35–36, 41, 43, 56ge, 58ge, 157–158, 169, 191–192, 334, 336 Neonatal-onset multisystem inflammatory disease, 54ge, 220ge chronic neurologic cutaneous and articular syndrome, 198 Neorickettsia sennetsu, 210–211, 218 Nephroblastomas, 30, 243 Nephronophthisis, 122–123, 351–352 Nerve cells, 143ge Nerve conduction, 82 Neural crest, 81–82, 84, 219ge, 235, 237–238, 254–256ge Neural tube, 237–238 defects, 121 Neurectoderm, 88, 105ge Neuroblastoma, 75, 95, 155–156, 293, 346 Neurocristopathy, 238, 256ge Neurofibrillary tangles, 126, 353 Neurofibroma, 56ge, 74–75, 313ge Neurofibromatosis, 27, 56–57ge, 74–75, 104ge, 109ge, 138, 145ge, 256ge, 313ge, 354ge Neuromuscular junctions, 138 Neuron, 51ge, 84, 100ge, 104ge, 107ge, 279 Neurotoxin, 300 Neutralizing autoantibodies, 137–138 Neutropenia, 49ge, 76, 83, 100ge, 133–134, 137, 197–198, 346 Nevocellular cells, 57ge New daily persistent headache, 207 New variant creutzfeldt jakob disease, 144ge NF-B activation disorders, 199 NKX2.5 homeobox gene, 53ge Nodding disease, 207–209 Nomenclature, 10ge, 12ge, 38, 59ge, 61ge, 216, 221ge, 223ge, 233, 241, 257ge, 282–284 Nomenclature code, 282–283 Noncoding region, 76–77, 101ge, 106ge, 118, 127, 158–159, 336 Nonconvergent disease, 124 Nonhistone chromatin complex, 84 Nonhistone nuclear protein, 88 Non-Hodgkin lymphoma, 349–350, 357ge Noninherited genetic disease, 33–34, 57ge Nonphylogenetic property, 187, 222ge Nonphylogenetic signal, 187, 222ge Nonquantitative data, 277–279 Nonsyndromic disease, 70, 105ge Nuclear atypia, 19–20, 55ge, 87–88, 89f, 102ge Nuclear membrane, 41, 87–88, 109ge Nucleoli, 41, 87–88, 89f Null hypotheses, 106ge, 314–315ge, 318ge NUT-1 Gene, 164–165t NUT midline carcinoma, 250 O Obesity, 11ge, 54ge, 72, 75, 103ge, 123, 143ge, 157–158, 162, 174ge, 337 Object oriented programming, 223ge, 254ge, 256ge, 266–267, 269, 311–312ge, 314ge Obligate intracellular organism, 190–191, 222ge Observational data, 349, 358ge Odontogenic keratocyst, 170, 175ge Off-label, 350, 358ge Oguchi disease, 73 Oligodendroglioma, 358ge Onchocerca volvulus, 208, 219ge Oncocyte, 159, 176ge Oncogene, 26–28, 34–35, 46–47, 48ge, 54ge, 57ge, 59ge, 80–81, 107ge, 143ge, 192, 222ge, 329, 357ge Ontology, 6, 9ge, 60ge, 232, 256ge, 306, 311ge O’nyong’nyong fever virus, 223ge Oocyte, 11ge, 52ge, 55ge, 107ge, 155 Open access, 303 Open reading frame (ORF), 70, 105ge Open source, 288, 290–291, 313ge Operating system, 232, 267, 272, 288, 313ge, 317ge Opisthokonts, 217, 241–242 Opisthorchis viverrini flatworm (fluke), 339 Opportunistic infection, 194, 205, 222ge Oral cancer, 159 ORF (open reading frame), 70, 105ge Orofaciodigital syndrome, 122–123 Orphan diseases, 154 Orphan drug, 160, 175ge, 345–346 Orthodisease, 354, 358ge Ortholog, 75–76, 105ge, 354 Orthologous gene, 105ge, 351, 354, 358ge Osteitis fibrosa cystica, 109ge Osteoarthritis, 94, 209 deformans endemica, 209 Osteomyelitis/synovitis, 198 Osteoporosis, 168–171 pseudoglioma syndrome, 170–171 Osteosarcoma, 73, 103ge Outcome data, 275, 290, 348–349 Outlier, 99ge, 275, 294–295, 302 Ovarian cancer, 103ge, 136–137, 344 Oxygenic photosynthesis, 191–192 P P53, 41, 73, 95, 103ge Palindrome, 290 Pancreatic islet, 20, 339 Pancytopenia, 49ge, 100ge, 104ge, 254ge PAPA. See Pyogenic arthritis, pyoderma gangrenosum, and acne (PAPA) Papanicolaou smear, 358ge Pap smear, 338, 358ge Paradox, 17–25, 231–233, 246–247, 256ge Paraganglia, 81 Paraganglial tumor, 81 Paraganglioma, 80–81, 83–84 Paralog, 105ge Paraneoplastic syndrome, 142ge, 144ge Paraphyly, 255ge Parasite, 53ge, 133, 172, 182, 194–196, 215, 217, 219–220ge, 223ge, 304 Parasitic organisms, 190–191, 223ge Parasympathetic, 135 Parent class, 8–9ge, 12ge, 189, 205, 222ge, 229–232, 252ge, 255–256ge, 267, 269, 311ge, 314ge Pareto’s principle, 314–315ge, 318ge Parkin knockout mice, 352 Parkinson disease, 6–7, 52ge, 54ge, 143ge, 164–165t, 171, 352–353 Paroxysmal nocturnal hemoglobinemia, 60ge Partial lipodystrophy, 330 Partial mole, 220ge, 257ge Partington syndrome, 53ge Pathway, 2, 18, 69–70, 117, 159, 184, 231, 269, 341 Pathway directed treatments, 135–145, 346–347 Pathway trials, 346 Patient confidentiality, 305 PDGFR. See Platelet derived growth factor receptor (PDGFR) Pelger-Huet anomaly, 88, 96, 128, 355ge Pembrolizumab, 140 Pemphigus, 132 Penetrance, 9ge, 27, 50ge, 57ge, 74, 144ge Percolozoan encephalitis, 213 Periodic fever syndrome, 198 Pernicious anemia, 128–130, 132–133 Peroxisome biogenesis disorder, 164 Peroxisome disorder, 222ge Personalized medicine, 2, 337 Petriellidium boydii, 216 Phakoma, 354 Pharmacogenomics, 305, 315ge Phenocopy disease, 105ge, 125–131, 145ge, 164, 352 Phenotype, 2, 23, 71–72, 117, 156, 197–198, 235, 303, 336 Phenotypic heterogeneity, 162, 175ge Phenylketonuria, 56ge, 160 Phenytoin embryopathy, 121–122 Pheochromocytoma, 80–81, 83 Philadelphia chromosome, 58ge Phocomelia, 83, 128, 168 Photosynthesis, 191–192, 219ge Phyllodes tumor, 73 Phylogenetic chronometer, 71 Phylogenetic classification, 358ge Phylogenetics, 72, 187, 217, 221–222ge, 253ge, 278, 358ge Phylogeny, 340, 358ge Pigmented villonodular synovitis, 207 Pityriasis rosea, 207 PiZZ variant, 83 Placenta, 192–193, 238–240, 255ge, 258ge Plasma cells, 31, 55–56ge, 134, 197, 218ge, 248–249, 249f Plasminogen deficiency, 354 Plasmodium knowlesi, 215 Plasmodium vivax malaria, 172, 196 Platelet derived growth factor receptor (PDGFR), 103ge, 140 PLEC gene, 73, 123–124 Pleiotropic, 72, 76, 105ge, 332–333 Pleiotropy, 144ge Plod2 gene (procollagen lysine dioxygenase 2), 142ge Pneumococcal disease, 164–165t, 195 Pneumocystis, 53ge, 216–217 Point mutation, 56–57ge, 59ge, 143ge, 331, 357ge Polyangiitis, 206–207 Polyarteritis nodosa, 207 Polycystic kidney disease, 122–123, 174ge Polycythemia, 56ge, 83, 105ge, 139, 165 Polygenic disease, 127, 131, 144ge, 157–158, 173–174ge, 333–334 Polymorphism, 8ge, 42, 54ge, 58ge, 78–79, 97, 102ge, 106ge, 118, 134, 143–144ge, 157–158, 174ge, 195–196, 220ge, 290, 312ge Polynucleotide repeat disorder, 108ge Polyvinyl chloride, 166 Population of the U.S, 11ge, 107ge, 154, 291 Porphyria cutanea tarda, 57ge, 127 Posterior cortical atrophy, 207 Posterior flagellum, 241–242 Postmitotic cell, 48, 58ge, 60ge, 98ge, 234 Post translational defects, 173ge Post translational modifications, 26, 58ge, 101ge, 164, 175ge Post-transplant lymphoproliferative disease, 55ge Potocki-Shaffer syndrome, 53ge Power law, 288, 291, 314–315ge, 356–357ge Power series, 288 Prader-Willi/Angelman syndrome, 75, 86, 103–104ge Precancer, 31–34, 46–47, 49–51ge, 53ge, 55–56ge, 58–59ge, 87–88, 203, 338 regression, 58ge Precancerous condition, 31, 58ge Precision data, 5, 263–318 diagnosis, 106ge, 215–216, 247–258, 338 medicine, 1–13, 17, 69–109, 117, 153–154, 160–162, 187, 234, 270, 285–298, 301, 327–358 taxonomy, 210–223 Preclinical trial, 352–353, 358ge Precursor lesions, 32, 44, 248 Precursors, 32–34, 44, 89, 95, 106ge, 134, 248, 252ge, 254–255ge Predictive analytics, 257ge, 357ge Predictive test, 10ge, 257ge Predictor, 257ge Premalignancy, 59ge Premature aging disorders, 71 Premature aging syndrome, 70, 101ge Prevalence, 11–12ge, 24, 27, 59ge, 101ge, 131, 154, 358ge Prevotella dentalis, 213 Primary biliary cirrhosis, 197 Primary cilia, 9ge, 123 Primary data, 307, 315ge Primary disease, 6, 9ge, 11–12ge, 92 vs. secondary disease, 10ge Primary effusion lymphoma, 45 Primary erythromelalgia, 10ge, 124–125 Primary host, 220ge, 223ge Prion, 144ge, 181, 183, 187, 203, 214, 221ge, 354 Prion disease, 119, 126, 144ge, 354 Privacy vs. confidentiality, 307, 315ge Prognosis, 2, 10ge, 95, 108ge, 250–252 Progressive neurodegenerative disorder, 71–72 Prokaryotes, 57ge, 183, 191, 213 Promoter, 46–47, 52ge, 56ge, 59ge, 100–101ge, 106ge, 219ge Promyelocytic leukemia, 87, 161 Properties vs. classes, 257ge Prospective clinical trial, 344, 349 Protein folding disorders, 199 Protein misfolding disorders, 198 Proto-oncogenes, 46–47, 48ge, 57ge, 59ge, 222ge Protozoa, 59ge, 205, 213, 216–217 Protozoal infections, 258ge Protozoans, 23, 59ge, 205, 216–217, 258ge Proviruses, 46 Proximate cause, 13ge, 37–38, 40, 59ge Prurigo nodularis, 207 Psammoma bodies, 126, 279 PSA value, 277 PSEN1 gene, 95 Pseudallescheria boydii, 216 Pseudallescheriosis, 216 Pseudoagouti, 86–87 Pseudoconvergent diseases, 124 Pseudodichotomy, 199, 243 Pseudogene, 85, 106ge Pseudo-Pelger-Huet, 128 Psoriasis, 139 Psychiatric disorder, 7 PTEN gene, 102ge, 156 Public Law, 11ge, 154, 346 Pulmonary alveolar proteinosis (PAPs), 126, 133, 137–138, 346 Putative causal oncogene, 28 P value, 314ge, 358ge Pyoderma gangrenosum, 54ge, 198, 220ge Pyogenic arthritis, 54ge, 198, 220ge Pyogenic arthritis, pyoderma gangrenosum, and acne (PAPA), 198 Pyruvate dehydrogenase, 100ge Q Quantitative traits, 136, 334 Quaternary disease, 12ge R Rag1 and Rag2 recombinase, 80 Ragged red fiber myopathy, 279 Rag genes, 192–193, 218ge Randomized control trial, 343, 348–349 Randomly occurring mutation, 98ge Random number, 266, 296–298 Rare diseases, 4, 19, 73, 122, 153–176, 204, 248, 289, 330 Act of 2002, 11ge, 154 Recessive polycystic kidney disease, 122–123 Recommender algorithms, 243–244, 258ge Redundant systems, 197 Reference laboratories, 213–214 Reflection, 30, 270, 313ge Refractory anemia, 97, 104ge Refsum disease, 222ge Regression, 33–34, 47, 50ge, 55–56ge, 58–59ge Regulatory element, 9ge, 42–43, 61ge, 76, 106ge, 145ge Reidentified record, 312ge Relapsing polychondritis, 197 Renal angiomyolipoma, 83, 102ge, 174ge Renal artery dysplasia, 136f Renal cell carcinoma (RCCs), 83, 106ge, 242–243, 282–283 Renal tubular acidosis, 128 Repeatability, 26, 343 Retinal dystrophy, 120, 122–123 Retinitis, 73 pigmentosa, 8ge, 70, 73, 101ge, 107ge, 119–120, 123, 142ge, 173ge Retrospective data, 349 Retrovirus, 46–47, 57ge, 59ge, 182, 190, 192–193, 199, 221–223ge, 339 Rett syndrome, 7, 90, 100ge Rhabdoid tumor, 47, 60ge, 88–90, 89f, 354 Rhabdoid tumor A, 60ge Rhabdomyosarcoma, 49ge, 103ge Rheumatic fever, 21–22, 132–133, 203, 233–234 Rheumatoid arthritis, 131–132, 134, 139, 197, 201, 346, 349–350 Rh incompatibility disease, 131 Rickettsia, 55ge, 191, 217, 221ge Rickettsiosis, 217 Rieger syndrome, 53ge Risk prediction, 248, 251–252 RNA polymerase, 59ge, 106ge, 219ge RNA silencing, 101ge RNA splicing, 85, 98ge RNA that might influence gene, 85 Roberts syndrome, 83, 128, 355ge Rochalimaea quintana, 217 Rod cone dystrophy, 72 Root cause, 2, 9–10ge, 12–13ge, 24–25, 46, 51ge, 56ge, 60ge, 71, 76–79, 81, 85, 89–90, 92, 96, 117, 121, 125, 127, 129, 137, 140, 144ge, 154–155t, 158–160, 188–189, 192–193, 195, 207, 303, 341, 345, 347–348, 351–352, 355ge Rubber and tire manufacturing industries, 166 Russell-Silver syndrome, 75, 86, 106ge S Sample contamination, 216, 300 Sample size, 106ge, 296, 298, 315ge Sampling errors, 278, 300 Sampling size, 298 SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis, and osteitis), 207 Sarcoglycan complex synthesis, 164 Sarcoglycanopathies, 164 Sarcoidosis, 54ge, 207, 220ge Sars virus, 219ge Schnitzler syndrome, 199 Schwannoma, 56ge, 138, 145ge SCID. See Severe combined immunodeficiency disease (SCID) SCN5A gene, 95 Screening tests, 248, 257ge, 338 Scurvy, 128, 233–234 Secondary data, 11ge, 315–316ge Secondary disease, 6, 9–12ge Secondary HLH, 199 Secretory breast carcinoma, 250 Self-limited disease, 210 Seminoma, 156–157, 161, 175ge, 238, 255ge, 339 Senior-Loken syndrome, 122–123 Serotype, 215, 223ge Serratia marcescens, 212 Severe combined immunodeficiency disease (SCID), 46, 72, 80, 84 SGCD gene, 95 Shagreen patches, 54ge Shoe industry workers, 166 Short rib polydactyly, 122–123 Short stature homeobox, 53ge Shwachman-Diamond syndrome, 24–25, 95–96 Sick building syndrome, 207 Sickle cell anemia, 119, 334, 354ge Sickle cell disease, 50ge, 56ge, 107ge, 119, 143ge, 160, 195, 334–335, 354ge Sideroblastic anemia, 97, 104ge, 128 Signaling pathway, 139, 170 Sign of Leser-Trelat, 144ge Silent mutation, 106ge Similarity scores, 282–283 Single gene disease, 70–71, 96, 105ge, 107ge Single nucleotide polymorphism (SNP), 56ge, 78–79, 98ge, 102ge, 106–107ge, 174ge, 336 in GWAS, 174ge Single nucleotide variant (SNV), 106ge Sister chromatid cohesion, 83 Situs inversus, 105ge, 124f Sjogren’s syndrome, 207 Sleeping sickness, 187–188 Small cell carcinoma, 173ge Small interfering RNA, 106ge Smallpox virus, 172 Smokovia, 18–19 Smoothened, a multifuctional protein, 170 Sodium channel, 10ge, 124–125, 142ge, 165 Soma, 34, 60ge Somatic mosaicism, 103ge, 107ge, 335 mutation, 33–34, 56ge, 59–60ge, 75, 98ge, 107ge, 165, 335–336, 357ge Soot, 166 Speciation, 35, 105ge, 258ge Species, 2, 8–10ge, 17, 21–22, 31–33, 35, 41–42, 49ge, 53ge, 60ge, 75–76, 104–106ge, 119–120, 142–144ge, 171–172, 181–184, 187–188, 188–189t, 190–191, 193–194, 196, 202–204, 210–211, 213–217, 219–221ge, 223ge, 230–231, 240–242, 248–249, 253ge, 255ge, 257ge, 280f, 284, 287–288, 332, 334, 351–354, 356ge, 358ge Spherocytosis, 70 Spliceosome disease, 107ge Spliceosome disorder, 98ge Spondyloarthropathies, 199 Spontaneous abortions, 128, 336 Spontaneous cerebrospinal fluid leak, 207 Spontaneously regressing diseases, 59ge Spontaneous regression, 33–34, 55ge Spontaneous vs. sporadic, 60ge Sporadic, 12ge, 24–25, 50ge, 60ge, 94–96, 119–120, 126, 171, 355ge prion disease, 119 retinoblastomas, 313ge Sporadic disease, 6, 24–25, 119, 293 vs. phenocopy disease, 145ge Sporozoite, 216–217 Squamous carcinoma, 33, 35, 45, 54ge, 107ge, 166, 173ge, 203 Src oncogene, 46–47 Staging, 245–246, 250–252, 258ge Statin, 4, 171–172 Statistical anomaly, 246–247 Stem cells, 30, 49ge, 52ge, 56ge, 58ge, 60–61ge, 101ge, 105ge, 107–108ge, 166 Stickler syndrome, 70 Stiff person syndrome, 207 Stoichiometric, 40–41 Stroke, 158, 182 Subclassify, 230–231, 245 Subpopulation of cells, 59ge, 73, 88, 238, 296 Subtypes of disease, 98ge, 250, 278, 292, 348 Succinate dehydrogenase (SDHB), 80–81 Sudden infant death syndrome (SIDS), 287 Sudden unexpected death syndrome, 207 SUMO, 256ge Superclass, 6, 8ge, 10ge, 12ge, 222ge, 232–239, 257ge, 286, 311ge Susceptibility, 2, 7ge, 12ge, 50ge, 73, 77–78, 91, 144ge, 157, 190, 195, 212, 222ge, 251, 332–333, 351 Susceptibility gene, 12ge, 77–78, 294 SV40-like polyoma virus, 339 SV40 virus, 339 Sweating sickness, 207 Syncytin, 193 Syncytiotrophoblasts, 238 Synovial osteochondromatosis, 207 Systemic lupus erythematosus, 133–134, 197, 251, 346, 349–350 T Taino, 189, 196 Takayasu’s arteritis, 207 Tangier disease, 127, 164 Targeted therapies, 94, 245 Tau encephalopathy, 128 Tau protein, 281, 354ge Taxon-A, 223ge Taxonomy, 6, 12ge, 97–98, 181–189 T cells, 46, 72, 80, 131, 161–162, 192–193, 197, 218ge, 339 Telomere, 354 Teratomas, 30, 238, 255ge Teratomatous neoplasms, 235 Tertiary disease, 11–12ge Thalamus, 159 Thalidomide, 128, 168 Thesaurus, 223ge Thorotrast, 166–167 Thrombocythemia, 56ge, 98ge, 105ge, 139, 165 Thyroid carcinoma, 12ge, 169, 181–189, 210–223, 232, 240–241, 253–254ge Ticks, 202, 223ge Tietz syndrome, 81–82 Time stamp, 264, 266–269, 271–272, 313ge, 317ge Timothy syndrome, 142ge Tnf receptor associated periodic syndrome, 220ge TNNC1 gene, 95 TNNT2 gene, 95 Torticollis, 138, 171, 207, 350 Totipotent stem cell, 56ge, 58ge, 61ge, 90–91, 235, 238, 255ge Toxin, 9ge, 18, 20, 22–23, 29–30, 44, 94, 101ge, 105ge, 129–130, 138, 143ge, 156–157, 159, 165–166, 168–169, 171, 194–196, 207, 235, 281, 350, 353–354 Toxoplasmosis, 184, 194–195, 339 TP53 gene, 71, 73 Trachoma, 208 Trans acting, 101ge, 108ge Transcription factor, 9ge, 42–43, 53ge, 58–59ge, 61ge, 76, 82, 101–102ge, 106ge, 118, 145ge Transdifferentiation, 108ge Transfected T cells, 162 Transgenic strain, 47, 76 Translational research, 141, 145ge Translation factor, 145ge Translocation, 48ge, 57–58ge, 87, 108–109ge, 222ge, 251 Transplacental carcinogenesis, 167, 175ge Transposable element, 223ge Transposon, 106ge, 190, 221ge, 223ge Trastuzumab, 348 Trench fever, 202 Trichodynia, 207 Trigger finger, 207 Trilateral retinoblastoma, 318ge Trinucleotide repeat disorder, 71–72, 108ge Triple, 42, 254ge, 267, 316ge Trophoblastic tumor, 238, 255ge Trophozoite, 216–217 Tropical sprue, 207 Trypanosoma brucei, 187–188 TSC2 gene, 139, 174ge Tuberculosis, 22, 27, 182, 189, 194–196, 339, 351 Tuberous sclerosis (TSC), 27, 54ge, 72, 95, 102–103ge, 138–139, 174ge, 354, 354ge Tubers, 102ge, 138, 354 Tumor necrosis factor receptor-associated periodic syndrome (TRAPS), 199 Tumor speciation, 35 Turner syndrome, 53ge Type 2 diabetes mellitus, 4, 11ge, 76, 121, 157, 199, 334 Type errors, 318ge Type II pneumocytes, 137 Tyrosine kinase, 58ge, 140–141, 161 U Ubiquitin protein, 61ge Ulcerative colitis, 293–294 Ultraviolet light, 77–78, 158 Unclassifiable objects, 258ge Undiagnosed JAK2 mutation, 165 Undifferentiated tumors, 108ge Unikonta, 186, 241–242 Uniparental disomy, 54ge, 98ge, 109ge Uniqueness, 2, 13ge, 264–265, 272, 275, 337 Universal and perpetual, 318ge Universally unique identifier (UUID), 265–266, 318ge Unphagocytosed organisms, 281 Ureteric bud, 242–243 Usher Syndrome, 70, 101ge, 122–123, 175ge U.S. Navy, 212 V Validation, 5–7, 13ge, 125, 301–302, 316ge, 342–343, 348–349 Vanishing bone disease, 206 Vanishing white matter, 145ge Variable expressivity, 74–76, 109ge Vascular endothelial growth factor, 120 Vascular malformation, 99ge Vector, 162, 202, 219ge, 223ge VEGFC, 120 Velocardiofacial syndrome, 104ge Ventilator tubes, 214 Verrucous carcinoma, 339 Vesicular trafficking disorders, 164, 173ge, 175ge Vesicular transport disorder, 175ge, 281, 354 Visceral situs anomalies, 122–123 Vital signs, 44, 328–329 Vitamin B, 97, 128 V(D)J recombination units, 80 Von Hippel-Lindau disease, 109ge Von Recklinghausen disease, 56ge, 109ge Von Willebrand disease, 127, 135 W Waardenburg syndrome, 53ge, 61ge, 81–82, 145ge Warfarin embryopathy, 121–122, 128 Warthin tumor, 159, 176ge Wegener’s syndrome, 206 Wernicke-Korsakoff syndrome, 159 West nile fever virus, 219ge WHIM, 76 Whipple disease, 203–204, 208, 281, 356ge Wild-type gene, 145ge Wilms tumors, 49ge, 53ge, 73, 243 Wilson disease, 128 Wolbachia pipientis, 208, 219ge Wolf-Hirschhorn syndrome, 53ge, 104ge Woolly hair, 70 World Health Organization, 13ge, 182, 216, 234, 337 Wrong statistical test, 318ge X X chromosome, 7, 85–86, 109ge, 279, 318ge, 336 Xeroderma pigmentosum, 109ge, 354 X-linked lymphoproliferative syndrome, 199 XML (eXtended Markup Language), 264–265, 317ge Y Y chromosome, 102ge, 109ge, 308, 318ge, 354ge Yellow fever virus, 219ge, 223ge Z Zebrafish, 195, 347–348, 351 Zika virus, 188t Zipf distribution, 291, 292f, 314–315ge, 358ge Zollinger-Ellison syndrome, 164–165t Zoonosis, 5, 26, 342 Zygote, 3, 35, 51–52ge, 54ge, 85, 107ge, 335–336, 356ge
Monday, January 22, 2018
Announcement: Precision Medicine and the Reinvention of Human Disease
In January, 2018, Academic Press is publishing my latest book, Precision Medicine and the Reinvention of Human Disease
Here is the book description, from the back cover:
Despite what you may have read in the popular press and in social media, Precision Medicine is not devoted to finding unique treatments for individuals, based on analyzing their DNA. To the contrary, the goal of Precision Medicine is to find general treatments that are highly effective for large numbers of individuals who fall into precisely diagnosed groups.
We now know that every disease develops over time, through a sequence of defined biological steps, and that these steps may differ among individuals, based on genetic and environmental conditions. We are currently developing rational therapies and preventive measures, based on our precise understanding of the steps leading to the clinical expression of diseases.
Precision Medicine and the Reinvention of Human Disease explains the scientific breakthroughs that have changed the way that we understand diseases, and reveals how medical scientists are using this new knowledge to launch a medical revolution.
Key Features
- Clarifies the foundational concepts of Precision Medicine, distinguishing this field from its predecessors such as genomics, pharmacogenetics, and personalized medicine.
- Gathers the chief conceptual advances in the fields of genetics, pathology, and bioinformatics, and synthesizes a coherent narrative for the field of Precision Medicine.
- Delivers its message in plain language, and in a relaxed, conversational writing style, making it easy to understand the complex subject matter.
- Guides the reader through a coherent and logical narrative, gradually providing expertise and skills along the way.
- Covers the importance of data sharing in Precision Medicine, and the many data-related challenges that confront this fragile new field.
Preface. Chapter 1. Introduction: Seriously, What is Precision Medicine? Glossary References Chapter 2. Redefining Disease Causality Section 2.1 Causality and Its Paradoxes Section 2.2 Why We Are Confident that Diseases Develop in Steps Section 2.3 Cause of Death Section 2.4 What Is a Disease Pathway? Section 2.5 Does Single Event Pathogenesis Ever Happen? Glossary References Chapter 3. Genetics: Clues, Not Answers, to the Mysteries of Precision Medicine Section 3.1 Inscrutable Genes Section 3.2 Inscrutable Diseases Section 3.3 Recursive Epigenomic/Genomic Diseases Section 3.4 Why a Gene-based Disease Classification Is a Bad Idea Glossary References Chapter 4. Disease Convergence Section 4.1 Mechanisms of Convergence Section 4.2 Phenocopy Diseases: Convergence Without Mutation Section 4.3 The Autoantibody Phenocopies Section 4.4 Pathway-Directed Treatments for Convergent Diseases Glossary References Chapter 5. The Precision of the Rare Diseases Section 5.1 The Biological Differences Between Rare Diseases and Common Diseases Section 5.2 Precision Medicine's First Benefit: Cures for Rare Diseases Section 5.3 What the Rare Diseases Tell Us About the Common Diseases Section 5.4 Treatments for Rare Diseases are Effective Against the Common Diseases Glossary References Chapter 6. Precision Organisms Section 6.1 Modern Taxonomy of Infectious Diseases Section 6.2 Our Genome Is a Book Titled "The History of Human Infections" Section 6.3 Inflammatory Diseases: Collateral Damage in the War on Human Infection Section 6.4 Revising Koch's Postulates in the Era of Precision Diagnostics Section 6.5 Diseases-in-waiting Section 6.6 Precision Taxonomy Glossary References Chapter 7. Reinventing Diagnosis Section 7.1 The Principles of Classification Section 7.2 Superclasses Section 7.3 Classifications Cannot Be Based on Similarities Section 7.4 The Horrible Consequences of Class Blending Section 7.5 What Is Precision Diagnosis? Glossary References Chapter 8. Precision Data Section 8.1 What Are the Minimal Necessary Properties of Good Data? Section 8.2 Data Identification and Data Deidentification Section 8.3 What Do We Do With Non-quantitative, Descriptive Data? Section 8.4 Incredibly Simple Methods to Understand Precision Medicine Data Section 8.5 Data Reanalysis: More important than the Original Data Analysis Section 8.6 What Is Data Sharing, and Why Don't We Do More of It? Glossary References Chapter 9. The Alternate Futures of Precision Medicine Section 9.1 Hypersurveillance Section 9.2 Do It Yourself Medicine Section 9.3 Eugenics Section 9.4 Public Health Section 9.5 The Data Analyst of Tomorrow Section 9.6 Fast, Cheap, Precise Clinical Trials Section 9.7 Animal Experimentation Glossary References
Tuesday, March 29, 2016
CLASS BLENDING: Simpson's Paradox
For the past two days, we've been posting on Class Blending. Simpson's paradox is a special case that demonstrates what may happen when classes of information are blended.
Simpson's paradox is a well-known problem for statisticians. The paradox is based on the observation that findings that apply to each of two data sets may be reversed when the two data sets are combined.
One of the most famous examples of Simpson's paradox was demonstrated in the 1973 Berkeley gender bias study (1). A preliminary review of admissions data indicated that women had a lower admissions rate than men:
A closer look at admissions department-by-department showed a very different story. Women were being admitted at higher rates than men, in almost every department. The department-by-department data seemed incompatible with the combined data.
The explanation was simple. Women tended to apply to the most popular and oversubscribed departments, such as English and History, that had a high rate of admission denials. Men tended to apply to departments that the women of 1973 avoided, such as mathematics, engineering and physics. Men tended not to apply to the high occupancy departments that women preferred. Though women had an equal footing with men in departmental admissions, the high rate of women rejections in the large, high-rejection departments, accounted for an overall lower acceptance rate for women at Berkeley.
Simpson's paradox demonstrates that data is not additive. It also shows us that data is not transitive; you cannot make inferences based on subset comparisons. For example in randomized drug trials, you cannot assume that if drug A tests better than drug B, and drug B tests better than drug C, then drug A will test better than drug C (2). When drugs are tested, even in well-designed trials, the test populations are drawn from a general population specific for the trial. When you compare results from different trials, you can never be sure whether the different sets of subjects are comparable. Each set may contain individuals whose responses to a third drug are unpredictable. Transitive inferences (i.e., if A is better than B, and B is better than C, then A is better than C), are unreliable.
- Jules Berman (copyrighted material)
key words: data science, irreproducible results, complexity, classification, ontology, ontologies, classifications, data simplification, jules j berman
Reference:
1. Bickel PJ, Hammel EA, O'Connell JW. Sex Bias in Graduate Admissions: Data from Berkeley. Science 187:398-404, 1975.
2. Baker SG, Kramer BS. The transitive fallacy for randomized trials: If A bests B and B bests C in separate trials, is A better than C? BMC Medical Research Methodology 2:13, 2002
Simpson's paradox is a well-known problem for statisticians. The paradox is based on the observation that findings that apply to each of two data sets may be reversed when the two data sets are combined.
One of the most famous examples of Simpson's paradox was demonstrated in the 1973 Berkeley gender bias study (1). A preliminary review of admissions data indicated that women had a lower admissions rate than men:
Men Number of applicants.. 8,442 Percent applicants admitted.. 44% Women Number of applicants.. 4,321 Percent applicants admitted.. 35%A nearly 10% difference is highly significant, but what does it mean? Was the admissions office guilty of gender bias?
A closer look at admissions department-by-department showed a very different story. Women were being admitted at higher rates than men, in almost every department. The department-by-department data seemed incompatible with the combined data.
The explanation was simple. Women tended to apply to the most popular and oversubscribed departments, such as English and History, that had a high rate of admission denials. Men tended to apply to departments that the women of 1973 avoided, such as mathematics, engineering and physics. Men tended not to apply to the high occupancy departments that women preferred. Though women had an equal footing with men in departmental admissions, the high rate of women rejections in the large, high-rejection departments, accounted for an overall lower acceptance rate for women at Berkeley.
Simpson's paradox demonstrates that data is not additive. It also shows us that data is not transitive; you cannot make inferences based on subset comparisons. For example in randomized drug trials, you cannot assume that if drug A tests better than drug B, and drug B tests better than drug C, then drug A will test better than drug C (2). When drugs are tested, even in well-designed trials, the test populations are drawn from a general population specific for the trial. When you compare results from different trials, you can never be sure whether the different sets of subjects are comparable. Each set may contain individuals whose responses to a third drug are unpredictable. Transitive inferences (i.e., if A is better than B, and B is better than C, then A is better than C), are unreliable.
- Jules Berman (copyrighted material)
key words: data science, irreproducible results, complexity, classification, ontology, ontologies, classifications, data simplification, jules j berman
Reference:
1. Bickel PJ, Hammel EA, O'Connell JW. Sex Bias in Graduate Admissions: Data from Berkeley. Science 187:398-404, 1975.
2. Baker SG, Kramer BS. The transitive fallacy for randomized trials: If A bests B and B bests C in separate trials, is A better than C? BMC Medical Research Methodology 2:13, 2002
Monday, March 28, 2016
Open for Comment
For the past several years, I've kept this blog closed to comments. Prior to that, most of the comments were thinly disguised advertisements for pharmaceuticals, and I got tired of rejecting them. For the past month or so, I've re-opened the blog for readers' comments, without announcing the change; just to check whether I'd be inundated with computer-generated promotions.
It seems that neither software agents or readers have noticed the change. So, please, if you are a human and would like to send a comment, feel free to use the comments link at the bottom of every post. Your comments will be moderated, but I intend to approve all blogs that are created by humans, and that do not promote products or services or other web sites. You are also welcome to comment on prior posts that appeared in the past month.
- Jules Berman
key words: blog, postings, comments, announcement, jules j berman
It seems that neither software agents or readers have noticed the change. So, please, if you are a human and would like to send a comment, feel free to use the comments link at the bottom of every post. Your comments will be moderated, but I intend to approve all blogs that are created by humans, and that do not promote products or services or other web sites. You are also welcome to comment on prior posts that appeared in the past month.
- Jules Berman
key words: blog, postings, comments, announcement, jules j berman
Sunday, March 27, 2016
Expunging a Blended Class: The Fall of Kingdom Protozoa
In yesterday's blog, we introduced and defined the term "Class blending". Today's blog extends this discussion by describing the most significant and most enduring class blending error to impact the natural sciences: the artifactual blending of all single cell organisms into the blended class, Protozoa.
For well over a century, biologists had a very simple way of organizing the eukaryotes (i.e., the organisms that were not bacteria, whose cells contained a nucleus) (1). Basically, the one-celled organisms were all lumped into one biological class, the protozoans (also called protists). With the exception of animals and plants, and some of the fungi (e.g., mushrooms), life on earth is unicellular. The idea of lumping every type of unicellular organism into one class, having shared properties, shared ancestry, and shared descendants, made no sense. What's more, the leading taxonomists of the nineteenth century, such as Ernst Haeckel (1834 - 1919), understood the class Protozoa was at best, a temporary grab-bag holding unrelated organisms that would eventually be split into their own classes. Well, a century passed, and complacent taxonomists preserved the Protozoan class. In the 1950s, Robert Whittaker elevated Class Protozoa as a kingdom in his broad new "Five Kingdom" classification of living organisms (2). This classification (more accurately, misclassification) persisted through the last five decades of the twentieth century.
Modern classifications, based on genetics, metabolic pathways, shared morphologic features, and evolutionary lineage, have dispensed with Class Protozoa, assigning each individual class of eukaryotes to its own hierarchical position. A simple schema demonstrates the modern classification of eukaryotes (3). Many modern taxonomists are busy improving this fluid list (vida infra), but, most significantly, Class Protozoa is nowhere to be found.
By lumping every single-celled organisms into one blended class, we have missed the opportunity to develop true class-based remedies for the most elusive disease-causing organisms on our planet. The past two decades have seen enormous progress in reclassifying the former protozoans. Unfortunately, the errors of the past are repeated in textbooks and dictionaries.
Here are three definitions of protozoa that I found on the web. Notice that these definitions don't even agree with one another. Notice that the first definition includes single celled organisms that may be free-living or parasitic. The second definition indicates that protozoans are obligate intracellular organisms. The third definition indicates that some protozoans are pathogenic in animals but omits mention of pathogenicity for other types of organisms. None of the definitions tell us that modern taxonomists have abandoned "protozoa" as a bona fide class of organisms.
References:
[1] Scamardella JM. Not plants or animals: a brief history of the origin of Kingdoms Protozoa, Protista and Protoctista. Internatl Microbiol 2:207-216, 1999.
[2] Hagen JB. Five kingdoms, more or less: Robert Whittaker and the broad classification of organisms. BioScience 62:67-74, 2012.
[3] Berman JJ. Taxonomic Guide to Infectious Diseases: Understanding the Biologic Classes of Pathogenic Organisms. Academic Press, Waltham, 2012.
- Jules Berman (copyrighted material)
key words: data science, irreproducible results, complexity, classification, ontology, ontologies, protozoa, Apicomplexa, protists, protoctista,jules j berman
For well over a century, biologists had a very simple way of organizing the eukaryotes (i.e., the organisms that were not bacteria, whose cells contained a nucleus) (1). Basically, the one-celled organisms were all lumped into one biological class, the protozoans (also called protists). With the exception of animals and plants, and some of the fungi (e.g., mushrooms), life on earth is unicellular. The idea of lumping every type of unicellular organism into one class, having shared properties, shared ancestry, and shared descendants, made no sense. What's more, the leading taxonomists of the nineteenth century, such as Ernst Haeckel (1834 - 1919), understood the class Protozoa was at best, a temporary grab-bag holding unrelated organisms that would eventually be split into their own classes. Well, a century passed, and complacent taxonomists preserved the Protozoan class. In the 1950s, Robert Whittaker elevated Class Protozoa as a kingdom in his broad new "Five Kingdom" classification of living organisms (2). This classification (more accurately, misclassification) persisted through the last five decades of the twentieth century.
Modern classifications, based on genetics, metabolic pathways, shared morphologic features, and evolutionary lineage, have dispensed with Class Protozoa, assigning each individual class of eukaryotes to its own hierarchical position. A simple schema demonstrates the modern classification of eukaryotes (3). Many modern taxonomists are busy improving this fluid list (vida infra), but, most significantly, Class Protozoa is nowhere to be found.
Eukaryota (organisms that have nucleated cells)
Bikonta (2-flagella)
Excavata
Metamonada
Discoba
Euglenozoa
Percolozoa
Archaeplastida, from which Kingdom Plantae derives
Chromalveolata
Alveolata
Apicomplexa
Ciliophora
Heterokontophyta
Unikonta
Amoebozoa
Opisthokonta
Choanozoa
Animalia
Fungi
Why is it important to expunge Class Protozoa from modern classifications of living organisms? Every class of living organism contains members that are pathogenic to other classes of organisms. To the point, most classes of organisms contain members that are pathogenic to humans, or to the organisms that humans depend on for their existence (e.g., other animals, food plants, beneficial organisms). There are way too many species of pathogens for us to develop specific drugs and techniques to control the growth of each disease-causing organism. Our only hope is to develop general treatments for classes of organisms, that share the same properties; hence the same weaknesses. For example, in theory, it's much easier to develop drugs that work on Apicomplexans that it is to develop separate drugs that work on each pathogenic species of Apicomplexan (3). By lumping every single-celled organisms into one blended class, we have missed the opportunity to develop true class-based remedies for the most elusive disease-causing organisms on our planet. The past two decades have seen enormous progress in reclassifying the former protozoans. Unfortunately, the errors of the past are repeated in textbooks and dictionaries.
Here are three definitions of protozoa that I found on the web. Notice that these definitions don't even agree with one another. Notice that the first definition includes single celled organisms that may be free-living or parasitic. The second definition indicates that protozoans are obligate intracellular organisms. The third definition indicates that some protozoans are pathogenic in animals but omits mention of pathogenicity for other types of organisms. None of the definitions tell us that modern taxonomists have abandoned "protozoa" as a bona fide class of organisms.
from: http://www.dictionary.com/browse/protozoan
Protozoan: Any of a large group of one-celled organisms (called protists) that live in water or as parasites. Many protozoans move about by means of appendages known as cilia or flagella. Protozoans include the amoebas, flagellates, foraminiferans, and ciliates.
from: www.medicinenet.com/script/main/art.asp?articlekey=5091
Protozoa: A parasitic single-celled organism that can divide only within a host organism. For example, malaria is caused by the protozoa Plasmodium.
from: http://www.merriam-webster.com/dictionary/protozoan
Protozoan: any of a phylum or subkingdom (Protozoa) of chiefly motile and heterotrophic unicellular protists (as amoebas, trypanosomes, sporozoans, and paramecia) that are represented in almost every kind of habitat and include some pathogenic parasites of humans and domestic animals.
References:
[1] Scamardella JM. Not plants or animals: a brief history of the origin of Kingdoms Protozoa, Protista and Protoctista. Internatl Microbiol 2:207-216, 1999.
[2] Hagen JB. Five kingdoms, more or less: Robert Whittaker and the broad classification of organisms. BioScience 62:67-74, 2012.
[3] Berman JJ. Taxonomic Guide to Infectious Diseases: Understanding the Biologic Classes of Pathogenic Organisms. Academic Press, Waltham, 2012.
- Jules Berman (copyrighted material)
key words: data science, irreproducible results, complexity, classification, ontology, ontologies, protozoa, Apicomplexa, protists, protoctista,jules j berman
Subscribe to:
Posts (Atom)





